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INTRODUCTION 
 
 Oral administration is the most convenient and preferred means of any drug delivery to 
the systematic circulation. Oral controlled release drug delivery have recently been of increasing 
interest in pharmaceutical field to achieve improved therapeutic advantages, such as ease of 
dosing administration, patient compliance and flexibility in formulation. This route has high 
patient acceptability, primarily due to ease of administration. Over the years, oral dosage forms 
have become increasingly sophisticated with major role being played by 0control release drug 
delivery system (CRDDS). CRDDS release drug at a predetermined rate, as determined by 
drug’s pharmacokinetics and desired therapeutic concentration. This help in achieving 
predictable drug plasma concentration required for therapeutic effect. The successful functioning 
of an oral CRDDS is determined by- 
     1. Physicochemical properties of the drug molecule like, the aquous solubility, intestinal 
permeability, pH- solubility profile, etc. 
     2. Pharmacokinetic profile of the drug. 
     3. The interaction of these properties with the anatomy and physiology of the GI tract. One 
such requisite for successful performance of oral CRDDS is that the drug should have the good 
absorption throughout the GI tract, preferably by passive diffusion. 
 
 Drugs that are easily absorbed from gastrointestinal tract (GIT) and have short half- lives 
are eliminated quickly from the systemic circulation. Frequent dosing of these drugs is required 
to achieve suitable therapeutic activity. To avoid this limitation, the development of oral 
sustained-controlled release formulations is an attempt to release the drug slowly into the 
gastrointestinal tract (GIT) and maintain an effective drug concentration in the systemic 
circulation for a long time (Ichikawa M et al, 1991). After oral administration, such a drug 
delivery would be retained in the stomach and release the drug in a controlled manner, so that the 
drug could be supplied continuously to its absorption sites in the gastrointestinal tract (GIT) 
(Streubel A et al, 2006). These drug delivery systems suffer from mainly two adversities: the 
short gastric retention time (GRT) and unpredictable short gastric emptying time (GET), which 
can result in incomplete drug release from the dosage form in the absorption zone (stomach or 
upper part of small intestine) leading to diminished efficacy of administered dose (Iannucelli V, 
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et al,1998) . To formulate a site-specific orally administered controlled release dosage form, it is 
desirable to achieve a prolong gastric residence time by the drug delivery. Prolonged gastric 
retention improves bioavailability, increases the duration of drug release, reduces drug waste, 
and improves the drug solubility that are less soluble in a high pH environment (Garg R, et al, 
2008). Also prolonged gastric retention time (GRT) in the stomach could be advantageous for 
local action in the upper part of the small intestine e.g. treatment of peptic ulcer, etc. 
Gastroretentive drug delivery is an approach to prolong gastric residence time, thereby targeting 
site-specific drug release in the upper gastrointestinal tract (GIT) for local or systemic effects. 
Gastroretentive dosage forms can remain in the gastric region for long periods and hence 
significantly prolong the gastric retention time (GRT) of drugs (Moes AJ et al, 1993). Over the 
last few decades, several gastroretentive drug delivery approaches being designed and 
developed, including: high density (sinking) systems that is retained in the bottom of the stomach 
(Rouge N,et al,.1998), low density (floating) systems that causes buoyancy in gastric fluid 
(Goole J,et al,. 2007) mucooadhesive systems that causes bioadhesion to stomach mucosa , 
unfoldable, extendible, or swellable systems which limits emptying of the dosage forms through 
the pyloric sphincter of stomach, super porous hydrogel systems , magnetic systems etc. 
(Fujimori J,et al,.1994). These efforts resulted in GRDFs that were designed, in large part, based 
on the following approaches. 
 
(a) Low density form of the DF that causes buoyancy in gastric fluid 
 (b) High density DF that is retained in the bottom of the stomach  
(c) Bioadhesion to stomach mucosa  
(d) Slowed motility of the gastrointestinal tract by concomitant administration of drugs or 
Pharmaceutical excipients 
(e) Expansion by swelling or unfolding to a large size which limits emptying of the DF through 
the pyloric sphincter. 
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BASIC GASTROINTESTINALTRACT PHYSIOLOGY 
 
 It is well recognized that the stomach may be used as a ‘depot’ for sustained-release (SR) 
dosage forms, both in human and veterinary applications. The stomach is anatomically divided 
into three parts: that occur fundus, body, and antrum (or pylorus). The proximal stomach, made 
up of the fundus and body regions, serves as a reservoir for ingested materials while the distal 
region (antrum) is the major site of mixing motions, acting as a pump to accomplish gastric 
emptying (Wilson CG, et al, 1998).  Gastric emptying occurs during fasting as well as fed states. 
The pattern of motility is however distinct in the 2 states. During the fasting state an 
interdigestive series of electrical events take place, which cycle both through stomach and 
intestine every 2 to 3 hours. This is called the interdigestive myloelectric cycle or migrating 
myloelectric cycle (MMC), which is further divided into following 4 phases as described by 
Wilson and Washington (Desai S. A 1984).  
1.  Phase I (basal phase) lasts from 40 to 60 minutes with rare contractions. 
2. Phase II (preburst phase) lasts for 40 to 60 minutes with intermittent action potential and 
contractions. As the phase progresses the intensity and frequency also increases gradually. 
3. Phase III (burst phase) lasts for 4 to 6 minutes. It includes intense and regular contractions for 
short period. It is due to this wave that all the undigested material is swept out of the stomach 
down to the small intestine. It is also known as the housekeeper wave. 
4. Phase IV lasts for 0 to 5 minutes and occurs between phases III and I of 2 consecutive cycles. 
 
Fig.1 Motility pattern in GIT 
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 After the ingestion of a mixed meal, the pattern of contractions changes from fasted to 
that of fed state (Edith Madithowitz et al, 1999). This is also known as digestive motility pattern 
and comprises continuous contractions as in phase II of fasted state. These contractions result in 
reducing the size of food particles (to less than 1 mm), which are propelled toward the pylorus in 
a suspension form. During the fed state onset of MMC is delayed resulting in slowdown of 
gastric emptying rate (Asane GS. et al 2007). 
 
SUITABLE DRUG CANDIDATES FOR GASTRORETENTION 
 
 In general, appropriate candidates for GRDDS are molecules that have poor colonic 
absorption but are characterized by better  absorption properties at the upper parts of the GIT: 
 
1. Narrow absorption window in GI tract,e.g., riboflavin and levodopa. 
   2.Primarily absorbed from stomach and upper part of GItract, e.g., calcium 
supplements,chlordiazepoxideand cinnarazine. 
3. Drugs that act locally in the stomach, e.g., antacids and misoprostol. 
4. Drugs that degrade in the colon, e.g., ranitidine HCl and metronidazole. 
5. Drugs that disturb normal colonic bacteria, e.g., amoxicillin trihydrate. 
 
DRUGS THOSE ARE UNSUITABLE FOR GASTRORETENTIVE DRUG DELIVERY 
SYSTEMS  
 
1) Drugs that have very limited acid solubility e.g.phenytoin etc. 
2) Drugs that suffer instability in the gastric environment e.g. erythromycin etc. 
3) Drugs intended for selective release in the colon e.g. 5- amino salicylic acid and 
corticosteroids etc. 
PHYSIOLOGICAL FACTORS CONTROLLING GASTRIC RETENTION OF DOSAGE FORMS 
The gastric retention time (GRT) of dosage forms is controlled by several factors such as density 
and size of the dosage form, food intake, nature of the food, posture, age, sex, sleep and disease 
state of the individual (e.g., gastrointestinal diseases and diabetes) and administration of drugs 
such as prokinetic agents (cisapride and metoclopramide). 
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1. Density of dosage form 
Dosage forms having a density lower than that of gastric fluid experience floating behavior and 
hence gastric retention  Baumgartner S et. Al 2000). A density of <1.0 gm/cm3 is required to 
exhibit floating property. However, the floating tendency of the dosage form usually decreases as 
a function of time, as the dosage form gets immersed into the fluid, as a result of the 
development of hydrodynamic equilibrium (Timmermans ,et al, 1990). 
 
2. Size of dosage form 
 
 The size of the dosage form is another factor that influences gastric retention. The mean 
gastric residence times of non-floating dosage forms are highly variable and greatly dependent 
on their size, which may be small, medium, and large units(Taisei Mushiroda et al,2000). In fed 
conditions, the smaller units get emptied from the stomach during the digestive phase and the 
larger units during the housekeeping waves. In most cases, the larger the size of the dosage form, 
the greater will be the gastric retention time because the larger size would not allow the dosage 
form to quickly pass through the pyloric antrum into the intestine. Thus the size of the dosage 
form appears to be an important factor affecting gastric retention (El-Kamel AH,et al,2002). 
 
3. Food intake and nature of food 
 
 Food intake, the nature of the food, caloric content, and frequency of feeding have a 
profound effect on the gastric retention of dosage forms. The presence or absence of food in the 
stomach influences the GRT of the dosage form. Usually, the presence of food increases the 
GRT of the dosage form and increases drug absorption by allowing it to stay at the absorption 
site for a longer time. The above results are supported by the experiments of Whitehead et al 
which show an increase in the relative heights of the floating units after meal consumption. Food 
habits affect the GRT in the following ways:- Fed or unfed state – under fasting conditions, the 
GI motility is characterized by periods of strong motor activity or the migrating myoelectric 
complex (MMC) that occurs every 1.5 to 2 hours. The MMC sweeps undigested material from 
the stomach and, if the timing of administration of the formulation coincides with that of the 
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MMC, the GRT of the unit can be expected to be very short. However, in the fed state, MMC is 
delayed and GRT is considerably longer. It was concluded that as meals were given at the time 
when the previous digestive phase had not completed, the floating form buoyant in the stomach 
could retain its position for another digestive phase as it was carried by the peristaltic waves in 
the upper part of the stomach. Nature of meal – feeding of indigestible polymers or fatty acid 
salts can change the motility pattern of the stomach to a fed state, thus decreasing the gastric 
emptying rate and prolonging drug release.Caloric content – GRT can be increased by four to 10 
hours with a meal that is high in proteins and fats. Frequency of feed – the GRT can increase by 
over 400 minutes when successive meals are given compared with a single meal due to the low 
frequency of MMC.(Whitehead L,at el.,1998).  
 
4. Effect of gender, posture and age 
 
 A study by Mojaverian et al15 found that females showed comparatively shorter mean 
ambulatory GRT than males, and the gastric emptying in women was slower than in men. The 
authors also studied the effect of posture on GRT, and found no significant difference in the 
mean GRT for individuals in upright, ambulatory and supine state. On the other hand, in a 
comparative study in humans by Gansbeke et al, the floating and non- floating systems behaved 
differently. In the upright position, the floating systems floated to the top of the gastric contents 
and remained for a longer time, showing prolonged GRT. But the non-floating units settled to the 
lower part of the stomach and underwent faster emptying as a result of peristaltic contractions, 
and the floating units remained away from the pylorus. However, in supine position, the floating 
units are emptied faster than non-floating units of similar size (Gansbeke BV,et al,. 1991).( 
Mojaverian P et al, 1988). Effect of buoyancy--On comparison of floating and nonfloating 
dosage units, it was concluded that regardless of their sizes the floating dosage units remained 
buoyant on the gastric contents throughout their residence in the gastrointestinal tract, while the 
non-floating dosage units sank and remained in the lower part of the stomach. Floating units 
away from the gastro- duodenal junction were protected from the peristaltic waves during 
digestive phase while the nonfloating forms stayed close to the pylorus and were subjected to 
propelling and retropelling waves of the digestive  phase.(Timmermans J,et al,1994). 
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TYPES OF GASTRORETENTIVE DOSAGE FORM 
 
1. FLOATING SYSTEM - Floating drug delivery systems (FDDS) have a bulk density less than 
gastric fluids and soremain buoyant in the stomach without affecting gastric emptying rate for a 
prolonged period of time. While the system is floating on the gastric contents, the drug is 
released slowly at the desired rate from the system (Taisei Mushiroda et. al., 2000). After release 
of drug, the residual system is emptied from the stomach. This results in an increased GRT and a 
better control of the fluctuations in plasma drug concentration. FDDS can be divided into non-
effervescent and effervescent system.  
 
 
Fig.2 Floating System 
 
 
Fig. 1:3 The mechanism of floating systems 
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A. NON EFFERVESCENT SYSTEMS- 
 
 This type of system, after swallowing, swells unrestrained via imbibition of gastric fluid 
to an extent that it prevents their exit from the stomach.One of the formulation methods of such 
dosage forms involves the mixing of the drug with a gel, which swells in contact with gastric 
fluid after oral administration and maintains a relative integrity of shape and a bulk density of 
less than one within the outer gelatinous barrier (Hilton AK,et al, 1992). The air trapped by the 
swollen polymer confers buoyancy to these dosage forms. Excipients used most commonly in 
these systems include hydroxypropylmethylcellulose(HPMC), polyacrylate polymers, polyvinyl 
acetate, Carbopol, agar, sodium alginate, calcium chloride, polyethylene oxide and 
polycarbonates. This system can be further divided into four sub- types: 
 
a. Colloidal gel barrier system- Sheth and Tossounian first designated this ‘hydrodynamically 
balanced system’s. Such a system contains drug with gel-forming hydrocolloids meant to remain 
buoyant on the stomach content. This prolongs GRT and maximizes the amount of drug that 
reaches its absorbtion sites in the solution form for ready absorption. This system incorporates a 
high level of one or more gel-forming highly soluble cellulose type hydrocolloid, e.g., 
hydroxypropyl cellulose, hydoxyethyl cellulose, hydroxypropyl methyl cellulose (HPMC), 
polysacharides and matrix-forming polymer such as polycarbophil, polyacrylate and polystyrene. 
On coming in contact with gastric fluid, the htdrocolloid in the system hydrates and forms a 
colloid gel barrier around its surface (Seth PR,et al,.1984). 
 
b. Microporous compartment system- This technology is based on the encapsulation of a drug 
reservoir inside a microporous compartment with pores along its top and bottom walls. The 
peripheral walls of the drug reservoir compartment are completely sealed to prevent any direct 
contact of gastric surface with the undissolved drug. In the stomach, the floatation chamber 
containing entrapped air causes the delivery system to float over the gastric content. Gastric fluid 
enters through the aperture, dissolves the drug and carries the dissolved drug for continuous 
transport across the intestine for absorption. (Harrigan RM et al,1977). 
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c. Alginate beads - Multi-unit floating dosage forms have been developed from freeze- dried 
calcium alginate. Spherical beads of approximately 2.5 mm in diameter can be prepared by 
dropping sodium alginate solution into aqueous solution of calcium chloride, causing the 
precipitation of calcium alginate. The beads are then separated, snap-frozen in liquid nitrogen, 
and freeze-dried at -40ºC for 24 hours, leading to the formation of a porous system, which can 
maintain a floating force for over 12 hours. These floating beads gave a prolonged residence time 
of more than 5.5 hours.(Whitehead L,et al,1996). 
 
 d. Hollow microspheres (microballoons) - 
 
 Hollow microspheres loaded with drug in their outer polymer shelf were prepared by a 
novel emulsion solvent diffusion method22. The ethanol/dichloromethane solution of the drug 
and an enteric acrylic polymer was poured into an agitated solution of Poly Vinyl Alcohol (PVA) 
that was thermally controlled at 40ºC. The gas phase is generated in the dispersed polymer 
droplet by the evaporation of dichloromethane formed and internal cavity in the microsphere of 
the polymer with drug. The microballoon floated continuously over the surface of an acidic 
dissolution media containing surfactant for more than 12 h. 
 
Fig.4: Hollow microspheres 
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B.EFFERVESCENT SYSTEMS- These buoyant systems utilize matrices prepared with 
swellable polymers such as methocel, polysaccharides (e.g., chitosan), effervescent components 
(e.g., sodium bicarbonate, citric acid or tartaric acid). The system is so prepared that upon arrival 
in the stomach, carbon dioxide is released, causing the formulation to float in the stomach. Other 
approaches and materials that have been reported are a mixture of sodium alginate and sodium 
bicarbonate (Arrora S, et al, 2005),multiple unit floating pills that generate carbon dioxide when 
ingested, floating minicapsules with a core of sodium bicarbonate, lactose and 
polyvinylpyrrolidone coated with hydroxypropyl methylcellulose (HPMC), and floating systems 
based on ion exchange resin technology, etc. 
 
a. Volatile liquid containing systems- These type of systems consist of two chambers separated 
by an impermeable, pressure-responsive, movable bladder. The first chamber contains the drug 
and the second chamber concotains the volatile liquid. The device inflates, and the drug is 
continuously released from the reservoir into the gastric fluid (Michaels, 1974). 
 
Fig. 5: Volatile liquid containing system 
 
b.Gas – generating systems- These buoyant delivery systems utilize effervescent reaction 
between carbonate/bicarbonate salts and citric/tartaric acid to liberate CO2, which gets entrapped 
in the gellified hydrocolloid layer of the systems, thus decreasing its specific gravity and making 
it float over chyme(Ichikawa, etal., 1991) 
 
Fig.6: Principle mechanism of floating by CO2 gas releasing method 
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2. BIO/MUCO–ADHESIVE SYSTEMS - 
 
 Bioadhesive drug delivery systems (BDDS) are used as a delivery device within the 
lumen to enhance drug absorption in a site-specific manner. This approach involves the use of 
bioadhesive polymers, which can adhere to the epithelial surface in the stomach (Dubernet C et 
al, 2004). Gastric mucoadhesion does not tend to be strong enough to impart to dosage forms the 
ability to resist the strong propulsion forces of the stomach wall. The continuous production of 
mucous by the gastric mucosa to replace the mucous that is lost through peristaltic contractions 
and the dilution of the stomach content also seem to limit the potential of  mucoadhesion as a 
gastroretentive force. Some of the most promising excipients that have been used commonly in 
these systems include polycarbophil, carbopol, lectins, chitosan and gliadin, etc. (Moes AJ. Gast, 
et al, 1993). 
 
Mechanism of bio/muco-adhesion- Binding of polymers to the mucin/epithelial surface can be 
devided into three categories: 
 
a.Hydration – mediated adhesion- Certain hydrophilic polymers have the tendency to imbibe 
large amount of water and become sticky, thereby acquiring bioadhesive properties. The 
prolonged gastroretention of the bio/muco-adhesive delivery system is further controlled by the 
dissolution rate of the polymer. 
 
b.Bonding –mediated adhesion- Adhesion of polymers to mucus/epithelial cell surface involves 
varying bonding mechanism.  hysical or mechanical bonds can result from deposition and 
inclusion of the adhesive material in the crevices of the mucusa. Secondary chemical bonds, 
contributing to bioadhesive properties, consist of dispersive intractions (i.e. van der Walls 
intractions) and stronger specific intraction, which include hydrogen bonds. The hydrophilic 
functional groups responsible for forming hydrogen bonds are the hydroxyl (--OH) and the 
carboxylic groups (--COOH) (Chien,1992).  
 
c.Receptor – mediated adhesion- Certain polymers have the ability to bind to specific receptor 
sites on the cell surface. The receptor mediated events serves as a potential approach in 
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bio/muco- adhesion, hence enhancing the gastric retention of dosage forms.  Certain plant 
lectins, like tomato lectins, interact specifically with the sugar groups present in mucus or on the 
glycocalyx.( Sharma S et, al., 2006). 
 
 
 
Fig. 7: Bio-adhesion system 
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 3.  SWELLING SYSTEMS - These are the dosage forms, which after swallowing, swell t an 
extent that prevents their exit from the   pylorus. As a result, the dosage form is retained in the 
stomach for a long period of time. These systems may be named as “plug type systems”, since 
they exibit the tendency to remain lodged at the pyloric sphincter. The formulation is designed 
for gastric retention and controlled delivery of the drug into the gastric cavity (Streubel A et. al., 
2006). Such polymeric matrices remain in the gastric cavity for several hours even in the fed 
state. Sustained and controlled drug release may be achieved by selection of proper molecular 
weight polymer, and swelling of the polymer retards the drug release. On coming in contact with 
gastric fluid, the polymer imbibes water and swells. The extensive of these polymers is due to the 
presence of physical/chemical cross-links in the hydrophilic polymernetwork.(Gupta,etal.,2002). 
 
Fig. 8: Swellable tablet in stomach 
 
4. HIGH DENSITY SYSTEMS-Sedimentation has been employed as a retention mechanism 
for pellets that are small enough to be retained in the rugae or folds of the stomach body near the 
pyloric region, which is the part of the organ with the lowest position in an upright posture. 
Dense pellets (approximately 3g/cm-3) trapped in rugae also tend to withstand the peristaltic 
movements of the stomach wall. With pellets, the GI transit time can be extended from an 
average of 5.8–25 hours, depending more on density than on the diameter of the pellets27. 
Commonly used excipients are barium sulphate, zinc oxide, titanium dioxide and iron powder, 
etc.These materials increase density by up to 1.5– 2.4g/cm-3.(Gehrke,1990). 
 
Fig. 9 : High density systems 
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5. Magnetic Systems - This approach to enhance the gastric retention time (GRT) is based on 
the simple principle that the dosage form contains a small internal magnet, and a magnet placed 
on the abdomen over the position of the stomach. Although magnetic system seems to work, the 
external magnet must be positioned with a degree of precision that might compromise patient 
compliance. (Whitehead, et al, 2000). 
 
ADVANTAGES OF GASTRORETENTIVE DRUG DELIVERY SYSTEMS 
 
 Enhanced bioavailability the bioavailability of riboflavin CR-GRDF is significantly 
enhanced in comparison to the administration of non-GRDF CR polymeric formulations. There 
are several different processes, related to absorption and transit ofthe drug in the gastrointestinal 
tract, that act concomitantly to influence the magnitude of drug absorption (Klausner EA, et al, 
2003). 
 
 Enhanced first-pass biotransformation In a similar fashion to the increased efficacy of 
active transporters exhibiting capacity limited activity, the pre-systemic metabolism of the tested 
compound may be considerably increased when the drug is presented to the metabolic enzymes 
(cytochrome P450, in particular CYP3A4) in a sustained manner, rather than by a bolus input. 
(Hoffman A, 1998). 
 
 Sustained drug delivery/reduced frequency of dosing For drugs with relatively short 
biological halflife, sustained and slow input from CR-GRDF may result in a flip-flop 
pharmacokinetics and enable reduced dosing frequency. This feature is associated with improved 
patient compliance, and thereby improves therapy. 
 
Targeted therapy for local ailments in the upper GIT 
 The prolonged and sustained administration of the drug from GRDF to the stomach may 
be advantageous for local therapy in the stomach and small intestine. By this mode of 
administration ,therapeutic drug concentrations may be attained locally while systemic 
concentrations, following drug absorption and distribution, are minimal. 
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Reduced fluctuations of drug concentration  
 Continuous input of the drug following CRGRDF administration produces blood drug 
concentrations within a narrower range compared to the immediate release dosage forms. Thus, 
fluctuations in drug effects are minimized and concentration dependent adverse effects that are 
associated with peak concentrations can be prevented. This feature is of special importance for 
drugs with a narrow therapeutic index (Hoffman A, 1999). 
 
Improved selectivity in receptor activation 
 Minimization of fluctuations in drug concentration also makes it possible to obtain 
certain selectivity in the elicited pharmacological effect of drugs that activate different types of 
receptors at different concentrations.  
 
Reduced counter-activity of the body 
 In many cases, the pharmacological response which intervenes with the natural 
physiologic processes provokes a rebound activity of the body that minimizes drug activity. Slow 
input of the drug into the body was shown to minimize the counter activity leading to higher 
drug efficiency. 
 
Extended time over critical (effective) concentration 
 For certain drugs that have non-concentration dependent pharmacodynamics, such as 
betalactam antibiotics, the clinical response is not associated with peak concentration, but rather 
with the duration of time over a critical therapeutic concentration. The sustained mode of 
administration enables extension of the time over a critical concentration and thus enhances the 
pharmacological effects and improves the clinical outcomes. 
 
Minimized adverse activity at the colon 
 
 Retention of the drug in the GRDF at the stomach minimizes the amount of drug that 
reaches the colon. Thus, undesirable activities of the drug in colon may be prevented. This 
pharmacodynamic aspect provides the rationale for GRDF formulation for beta-lactam 
antibiotics that are absorbed only from the small intestine, and whose presence in the colon leads 
to the development of microorganism’s resistance.  
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Site specific drug delivery 
 
 A floating dosage form is a feasible approach especially for drugs which have limited 
absorption sites in upper small intestine30. The controlled, slow delivery of drug to the stomach 
provides sufficient local therapeutic levels and limits the systemic exposure to the drug. This 
reduces side effects that are caused by the drug in the blood circulation. In addition, the 
prolonged gastric availability from a site directed delivery system may also reduce the dosing 
frequency. 
 
Limitations- 
 GRDDS have potential in improving BA of drugs exhibiting ‘absorption window’. 
However they have certain limitations. One of the major disadvantages of the floating system is 
the requirement of high levels of fluids in the stomach for the delivery system to float and work 
efficiently (Deshpande, et al, 1997). 
 
1. Require a higher level of fluids in the stomach. 
2. Not suitable for Drugs that... 
a. Have solubility problems in gastric fluid.E.g. phenytoin 
b. Cause G.I irritation. eg. NSAIDS. 
c. Are unstable in acidic environment. 
3. Drugs intended for selective release in the colon E.g. 5- amino salicylic acid and 
corticosteroids etc. 
4. The floating systems in patients with achlorhydria can be questionable in case of swellable 
system. 
5. Retention of high density systems in the antrum part under the migrating waves of the stomach 
is questionable. 
6. The mucus on the walls of the stomach is in a state of constant renewal, resulting in 
unpredictable adherence. 
7. The mucus on the walls of the stomach is in a state of constant renewal, resulting in 
unpredictable adherence. 
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REVIEW OF LITERATURE 
 
1. Kumar et al demonstrated works on the gastroretentive dosage forms for prolonging 
gastric residence time. In the study, the concepts of gastric emptying and absorption 
windows and current technological developments in gastroretentive drug delivery 
systems were discussed including their advantages and disadvantages  alongwith various 
evaluation techniques and marketed products for gastroretentive drug delivery. According 
to the authors, the bioadhesive superporous hydrogel, floating and expanding systems 
showed the most promising potential for achieving the goal of gastroretention. 
 
2. El-Kamal et al prepared and evaluated ketoprofen floating oral delivery system. They 
designed sustained release system for ketoprofen to increase its residence time in the 
stomach without contact with the mucosa which was achieved through the preparation of 
floating microparticles by the emulsion-solvent diffusion technique. They used four 
different ratios of Eudragit S100 with Eudragit RL to form the floating microparticles. It 
was found that release rates were generally low in 0.1 N HCl especially in presence of 
high content of Eudragit S100 while in phosphate buffer pH 6.8, high amounts of 
Eudragit S100 tended to give a higher release rate. 
 
3. Ali et al formulated hydrodynamically-balanced  system for metformin as a single unit-
floating capsule.The formulation was optimized on the basis of in vitro buoyancy and in 
vitro release in simulated fed state gastric fluid. Effect of various release modifiers was 
studied to ensure the delivery of drug from the HBS capsules over a prolonged period. 
Capsules prepared with HPMC K4M and ethyl cellulose gave the best in vitro percentage 
release and were taken as the optimized formulation. 
 
4. Patel et al developed and optimized a controlled- release multiunit floating system of 
ranitidine HCl  sing compritol, gelucire 50/13 and geliucire 43/01 as lipid carriers. 
Ranitidine HCl lipid granules were prepared by the melt granulation technique and 
evaluated for in vitro floatinganddrugrelease. Ethylcellulose, methylcellulose and 
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hyroxypropyl methylcellulose were evaluated as release rate modifiers. They concluded 
that the hydrophobic lipid Gelucire 43/01 could be considered an effective carrier for 
design of a multiunit floating drug delivery system for highly water-soluble drugs such as 
ranitidine HCl. 
 
5. Sahoo et al formulated floating microspheres of  Ciprofloxacin HCl by cross-linking 
technique. A polymeric mixture of sodium alginate and hydroxy propyl methyl cellulose 
(HPMC) was used. Sodium bicarbonate was used as gas forming agent. The solution was 
dropped to 1% calcium chloride solution containing 10% acetic acid for carbon dioxide 
release and gel formation. The prepared floating microspheres were evaluated with 
respect to particle size distribution, floating behavior, drug content, entrapped 
morphology and in vitro release study. Effect of sodium bicarbonate on the above 
mentioned parameters were evaluated and it was found that sodium bicarbonate had a 
pronounced effect on various parameters.  
 
6. Choia et al reported preparation of alginate beads for floating drug delivery system and 
studied the effects of CO2 gas forming agents. Floating beads were prepared from a 
sodium alginate solution containing CaCO3 or NaHCO3 as gas-forming agents. They 
studied the release characteristics of riboflavin as a model drug. Release rate of riboflavin 
increased proportionally with addition of NaHCO3. The results of these studies indicate 
that CaCO3 is superior to NaHCO3 as gas forming agent in alginate bead preparations. 
 
7. Sharma and Pawar et al developed low-density multi particulate system for pulsatile 
release of meloxicam for which they combined the principles of floating and pulsatile 
drug delivery system. They prepared multi particulate floating pulsatile drug delivery 
system using porous calcium silicate and sodium alginate for time and site-specific drug 
release of Meloxicam. 
 
8. Jaimini et al formulated and evaluated Famotidine floating tablets. They used Methocel 
K100 and Methocel K 15 M with effervescent mixture. It was observed that decrease in 
the citric acid level increased the floating lag time but tablets floated for longer duration. 
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A combination of sodium bicarbonate (130 mg) and citric acid (10mg) was found to 
achieve optimum in vitro buoyancy. They reported that tablets prepared with k 100 had 
longer floating time compared with formulations containing Methocel K15 M. 
 
9. Dave et al reported a gastroretentive drug delivery system of ranitidine hydrochloride. 
Guar gum, xanthan gum, and hydroxy propyl methylcellulose were evaluated for gel 
forming properties. Sodium bicarbonate was incorporated as a gas-generating agent. They 
investigated the effect of citric acid and stearic acid on drug release profile and floating 
properties. They concluded that the proper balance between a release rate retardant and a 
release rate enhancer could produce a drug dissolution profile similar to a theoretical 
dissolution profile. 
 
10.  Narendra et al reported optimization of bilayer floating tablet containing metoprolol 
tartrate as a model drug for gastric retention. They employed a 23 factorial design in 
formulating the GFDDS with total polymer content-to-drug ratio (X1), polymer-to-
polymer ratio (X2), and different viscosity grades of HPMC (X3) as independent 
variables. The results indicate that X1 andX2 significantly affected the floating time and 
release properties but the effect of different viscosity grades of HPMC (K4M and K10M) 
was non-significant. 
 
11. Sunil et al prepared floating microspheres consisting of calcium silicate as porous carrier 
and Eudragit S as polymer by solvent evaporation method and evaluated their 
gastroretentive and controlled release    properties. They studied the effect of various 
formulation and  process variables on the particle morphology,micromeritic properties, in 
vitro percentage drug entrapment and in vitro drug release. Prolonged gastric residence 
time of over six hours was achieved in rabbits for calcium silicate based floating 
microspheres of orlistate. The enhanced elimination half-life observed after 
pharmacokinetic investigation is due to the floating nature of the designed formulations.  
 
12.  Umamaheswari et al prepared floating-bioadhesive microspheres containing 
acetohydroxamic acid for clearance of Helicobacter Pylori. They explored a synergism 
Review Of Literature 
 
Dept of Pharmaceutics, Annai veilankanni’s pharmacy college, chennai                                                          20 
 
between a floating and a bioadhesive system.Floating microspheres containing the 
antiurease drug acetohydroxamic acid were prepared by a novel quasi emulsion solvent 
diffusion method. The microballons were coated with 2% w/v solution of polycarbophil 
by the air suspension coating method. The results suggested that AHA-loaded floating 
microspheres were superior as potent urease inhibitor whereas urease plays an important 
role in the colonization of H. Pylori. 
 
13.  Patel et al developed ranitidine floating tablets; in which they optimized types of filler, 
different viscosity grades of HPMC and its concentration. Two fillers namely Avicel pH 
102 and Tablettose 80 were used. Study revealed that type of filler had significant effect 
on release of drug from hydrophilic matrix tablets (f2 value 41.30) and floating 
properties. Three different viscosity grades of HPMC namely K100 LV, K4M and K15M 
were used. Viscosity had a major influence on drug release from hydrophilic matrices as 
well as on floating properties. The drug release from hydrophilic matrices occurred via 
diffusion mechanisms following square root  of time profile. Hardness of tablets had 
greater influence on floating lag time which might be due to decreased porosity whereas 
the position of paddle and types of dissolution medium had no significant effect on drug 
release. 
 
14. Srivastava et al  prepared floating matrix tablets of atenolol to prolong gastric residence 
time and  increase drug bioavailability. The tablets were prepared by direct compression 
technique, using polymers such as HPMC K15M, K4M, Guargum (GG), and sodium 
carboxy  methylcellulose (SCMC), alone or in   combination and  other standard 
excipients. Tablets were evaluated for physical characteristics like hardness, swelling 
index, floating capacity, thickness and weight variation. The effect of effervescent on 
buoyancy and drug release pattern was also studied. In vitro release mechanism was 
evaluated by linear regression analysis. GG- and SCMC- based matrix tablets showed 
significantly greater swelling indices compared with other batches. The tablets exhibited 
controlled and prolonged drug release profiles while floating over the dissolution 
medium.  
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15. Gohel et al developed a more relevant in vitro dissolution method to evaluate a 
carbamazepine floating drug delivery systems. The glass beaker was modified by adding 
a side arm at the bottom of the beaker so that the beaker can hold 70 ml of 0.1 N HCl 
dissolution mediums and allow collection of samples. The tablet did not stick to the 
agitating device in the proposed dissolution method. The drug release followed zero order  
kinetics in the proposed method. The proposed test may show good in vitro in vivo 
correlation (IVIVC) since an attempt is made to mimic the in vivo conditions. 
 
16. Amin et al developed a gastroretentive drug delivery system of ranitidine hydrochloride 
which was designed using guar gum, xanthan gum and HPMC. Sodium bicarbonate was 
incorporated as a gas-generating agent. The effect of citric acid and stearic acid on drug 
release profile and floating properties was investigated. The addition of stearic acid 
reduces the drug dissolution due to its hydrophobic nature. A 32 full factorial design was 
applied to systemically optimize the drug release profile and the results showed that a low 
amount of citric acid and a high amount of stearic acid favor sustained release of 
ranitidine HCl from a gastroretentive formulation. 
 
17. Streubel et al prepared single-unit floating tablets based on polypropylene foam powder 
and matrix-forming polymer. Incorporation of highly porous foam powder in matrix 
tablets provided density much lower than the density of the release medium. A 17% w/w 
foam  powder was achieved in vitro for at least 8 hours. It was concluded that varying the 
ratios of matrix-forming  polymers and the foam powder could alter the drug release 
patterns effectively.  
 
18. Li et al evaluated the contribution of formulation variables on the floating properties of a 
gastro floating drug delivery system using a continuous floating monitoring device and 
statistical experimental design. The formulation was conceived using 2x3 full factorial 
designs for calcium delivery. HPMC was used as a low- density polymer and citric acid 
was incorporated for gas generation. Analysis of variance (ANOVA) test on the results 
from these experimental designs demonstrated that the hydrophobic agent magnesium 
stearate could significantly improve the floating capacity of the delivery system. High-
viscosity polymers had good effect on floating properties. The residual floating force 
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values of the different grades of HPMC were in the order K4 M~ E4 M~K100 LV> E5 
LV but different polymers with same viscosity, i.e., HPMC K4M, HPMC E4M did not 
show any significant effect on floating property. Better floating was achieved at a higher 
HPMC/carbopol ratio and this result demonstrated that carbopol has a negative effect on 
the floating behavior. 
 
19. Sangekar et al studied the effect of food and specific gravity on the gastric retention time 
of floating (spec. grav. 0.96) and non-floating (spec. grav. 1.59) tablet formulations was 
investigated using gamma scintigraphy in humans. The results obtained indicate that the 
presence of food in the stomach appears to significantly prolong gastric retention of both 
the floating and non- floating tablets while specific gravity does not seem to play an 
important role in the residency time of the tablets in the stomach. 
 
20.  Xiaoqiang et al developed hydrodynamically balanced sustained release tablets 
containing drug and hydrophilic hydrocolloids which on contact with gastric fluids at 
body temperature formed a soft gelatinous mass on the surface of the tablet and provided 
a water-impermeable colloid gel barrier on the surface of the tablets. The drug slowly 
released from the surface of the gelatinous mass that remained buoyant on gastric fluids. 
 
21. Rahman et al developed a bilayer-floating tablet (BFT) for captopril using direct 
compression  technology. HPMC, K-grade and effervescent mixture of citric acid  and 
sodium bicarbonate formed the floating layer. The release layer contained captopril and 
various polymers such as HPMC-K15M, PVP-K30 and Carbopol 934p, alone or in 
combination with the drug. The floating behavior and in vitro dissolution studies were 
carried out in a USP 23 apparatus 2 in simulated gastric fluid (without enzyme, pH 1.2). 
Final formulation released approximately 95% drug in 24 h in vitro, while the floating lag 
time was 10 min and the tablet remained  loatable throughout all studies. Final 
formulation followed the higuchi release model and showed no significant change in 
physical appearance, drug content, floatability or in vitro dissolution pattern after storage 
at 45 °C/75% RH for three months. 
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22.  Bomma et al prepared floating matrix tablets of  norfloxacin which were developed to 
prolong gastric residence time leading to an increase in drug bioavailability by using wet 
granulation technique using polymers such as HPMCK4M, HPMCK100M and Xanthan 
gum. The tablets exhibited controlled and prolonged drug release profile while floating 
over dissolution medium was confirmed as drug release mechanism from these tablets. 
 
23. Thakkar et al formulated and evaluated the  levofloxacin hemihydrate floating tablets 
that were prepared by direct compression method using gelucire 43/01 and HPMC 
polymers in different ratio. The in vitro release study revealed the fact that the release 
rate of drug was decreased by increasing the proportions of gelucire 43/01 by 5 to 40% 
matrix tablets containing 25% HPMCK4M and 15% gelucire 43/01. 
 
24.  Rao et al formulated and optimized the floating drug delivery system of cephalexin. 
Tablets were prepared by direct compression method incorporating HPMCK4M, xanthan 
gum, guar gum, sodium bicarbonate and tartaric acid as gas generating agent. The 
diffusion exponent of  krosmeyer peppas for optimized formulation was found to be 
0.635 which significantly indicated the mechanism of drug release. 
 
25. Rohilla Ankur et al  Gastroretentive drug delivery system has been a significant 
approach over the past few years that have been noted to prolong gastric residence time, 
thereby targeting site-specific drug release in the upper gastrointestinal (GI) tract for local 
or systemic effects. The present study has been investigated to compile the recent as well 
as past literature with special focus on various gastroretentive approaches that have 
recently become leading methodologies in the field of site-specific orally administered 
controlled release drug delivery. Floating systems have been considered as one of the 
imperative categories of drug delivery systems with gastric retentive behavior. The 
review article explains the various floating drug delivery systems that are formulated in 
order to enhance the drug bioavailability. Moreover, various gastroretentive approaches 
designed and developed such as high density, floating, bioadhesive, super porous 
hydrogel and magnetic systems have been clearly discussed in the article.  
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26. Sunil Kumar et al    The purpose of writing this review on gastroretentive drug delivery 
systems was to compile the recent literature with special focus on various gastroretentive 
approaches that have recently become leading methodologies in the field of site-specific 
orally administered controlled release drug delivery. In order to understand various 
physiological difficulties to achieve gastric retention, we have summarized important 
factors controlling gastric retention. Gastro retention would also facilitate local drug 
delivery to the stomach and proximal small intestine. Thus, gastroretention could help to 
provide greater availability of new products and consequently improved therapeutic 
activity and substantial benefits to patients. Controlled gastric retention of solid dosage 
form may be achieved by the mechanisms of floatation, mucoadhesion, sedimentation, 
expansion or by a modified shaped system. 
 
27. K.R. Vinod et al Gastro retentive drug delivery systems were designed to prolong the 
gastric residence time in the stomach. The objective of the present study is to prepare the 
floating microspheres of Lansoprazole and sustain the drug release for longer time to 
overcome the short half life of the drug. Floating microspheres with four different 
variabilities in ratios of polymer and calcium carbonate were formulated by non-aqueous 
solvent evaporation method and in vitro evaluations were performed. Calcium carbonate 
acts as an effervescent agent as well as providing alkaline microenvironment for acid 
labile Lansoprazole. Drug: polymer 1:2 ratio gave the best result with 86.67% maximum 
release extended through a period of 11hrs. It was observed that as the polymer 
concentration along with calcium carbonate increases the buoyancy of microspheres also 
extended proportionally. SEM studies of microspheres showed good topology and the 
size was 355 μm. The cumulative % drug release in simulated gastric fluids after 10 
hours was 71.3%- 86.67%. Model fitting analysis revealed the release pattern was 
following Korsmeyer-Peppas for all formulations by obtaining maximum r
2
 value. 
 
28. A. M. Mahale et al Sustained release micro particles are mainly oral dosage forms 
consisting of a multiplicity of small discrete units, the active substance is present as a 
number of small independent subunits with diameter of 0.05-2.00mm.These subunits like 
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pellets, microcapsules, microspheres are filled into a sachet and encapsulated or 
compressed into a tablet. There are many reasons for formulating a drug as a sustained 
release micro particles for example, to facilitate disintegration in the stomach, or to 
provide a convenient, fast disintegrating tablet that dissolves in water before swallowing 
which can aid compliance in older patients and children. Sustained release micro particles 
show better reproducible pharmacokinetic behavior than conventional (monolithic) 
formulations. The individual subunit particles pass rapidly through the GI tract. They 
provide many advantages over single unit systems because of their small size. 
Multiparticulates are less dependent on gastric empty ting, resulting in less inter and 
intra-subject variability in gastrointestinal transit time. They are also better  distributed 
and less likely to cause local irritation. Recently much emphasis is being laid on the 
development of sustained release micro particles dosage forms in preference to single 
unit systems because of their potential benefits such as increased bioavailability, reduced 
risk of systemic toxicity, reduced risk of local irritation and predictable gastric emptying. 
Sustained release forms are designed for the normal population that is one the basis of 
average drug biological half lives. Consequently, Disease states that alter drug 
disposition, significant patient variation and so forth are not accommodated. Economical 
factors must be assessed since more costly process and equipment are involved in 
manufacturing. 
29. Mahesh Chavanpatil et al  Sustained release (SR)-gastroretentive dosage forms (GRDF) 
enable prolonged and continuous input of the drug to the upper parts of the 
gastrointestinal (GI) tract and improve the bioavailability of medications that are 
characterized by a narrow absorption window. A new strategy is proposed for the 
development of gastroretentive dosage forms for Ofloxacin preferably once daily. The 
design of the delivery system was based on the sustained release formulation, with 
floating and swelling features in order to prolong the gastric retention time of the drug 
delivery systems. Different polymers, such as psyllium husk, HPMC K100M, 
crospovidone and its combinations were tried in order to get the desired sustained release 
profile over a period of 24 h. Various formulations were evaluated for buoyancy lag time, 
duration of buoyancy, dimensional stability, drug content and in vitro drug release 
profile. It was found that dimensional stability of the formulation increases with the 
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increasing psyllium husk concentration. It was also found that in vitro drug release rate 
increased with increasing amount of crospovidone due to the increased water uptake, and 
hence increased driving force for drug release. The optimized formulation was subjected 
to stability studies at different temperature and humidity conditions as per ICH 
guidelines. In vivo studies were carried out for the optimized formulation in 24 healthy 
human volunteers and the pharmacokinetic parameters of developed formulations were 
compared with the marketed once daily (Zanocin) formulation. Based on the in vivo 
performance in a parallel study design in healthy subjects, the developed formulation 
shows promise to be bioequivalent to the marketed product (Zanocin). The percent 
relative bioavailability of developed formulation was found to be 97.55%. 
30.  Veerareddy et al The aim of the present investigation was to develop and evaluate 
gastroretentive drug delivery tablets (GRDDTs) of Ofloxacin using different polymers 
such as HPMC K4M, HPMC K15M, Polyethylene oxide WSR 303, Carbopol 971P, 
Xanthan Gum in different ratios for local action in gastric region to eradicate 
Helicobacter pylori infection. The GRDDTs were prepared by wet granulation method 
and evaluated for physical characteristics such as hardness, thickness, friability, drug 
content and floating properties. The optimized formula F4 showed better sustained drug 
release and which also had good floating properties and fitted best to be Korsmeyer-
Peppas model with R2 value of 0.9848. As the n value for the Korsmeyer- Peppas model 
was found be less than 0.45 it follows Fickian diffusion mechanism. FT-IR result showed 
that there is no drug excipient interaction. In vivo radiographic studies were conducted 
with BaSO4 loaded tablets to examine the increased gastric residence time of the 
prepared tablets. The study revealed that the tablet remained in the stomach for 
300±10min which indicates the increase in the gastric residence time for the effective 
localized action of the Ofloxacin in the treatment of Helicobacter pylori caused peptic 
ulcer. 
31. D. Saravanan et al  The present study outlines a systematic approach for designing and 
development of Ofloxacin floating tablets to enhance the bioavailability and therapeutic 
efficacy of the drug. Floating tablets of Ofloxacin have shown controlled release thereby 
proper duration of action at a particular site and are designed to prolong the gastric 
residence time after oral administration. Different formulations were formulated by wet 
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granulation technique using HPMC K4M, HPMC K15M and HPMC K100M (floating 
agent) as polymers along with sodium bicarbonate as gas generating agent. The 
formulations were evaluated for their physicochemical properties, buoyancy lag time, 
total floating time, swelling index and invitro drug release. It was found that the hardness 
of the tablets affects the Buoyancy characteristic of the dosage form. All six formulations 
possessed good floating properties with total floating time between 8 – 12 hrs. The 
invitro cumulative % drug release of the formulations F1A, F1B, F2A, F2B, F3A and 
F3B were 102.85%, 101.32%, 100.2%, 99.98%, 99.28% and 97.25%. 
 
32.  Golam Kibria et al  Extended release formulation of alfuzosin, an -antagonist used for 
prostatic hypertrophy, is available in market. It is convenient for older patients to take 
only one tablet a day. Marketed alfuzosin formulation is three layered geomatrix tablet 
that requires special facilities, high cost, more time and complex operation than normal 
direct compression formulation. Therefore, a less complicated formulation is desired 
which can be prepared by conventional tools. The aim of the study was the development 
and in vitro evaluation of a controlled release dosage form of a freely soluble weakly 
basic drug (alfuzosin hydrochloride). Binary mixer of one hydrophilic polymer 
(hydroxypropyl methylcellulose) and one hydrophobic polymer (ethyl cellulose) was 
used in tablets prepared by direct compression, 32 factorial design was chosen and the 
amount of two polymers were taken as independent variables. The percent drug released 
at 1, 6, 12, and 20 h were selected as response. The main effect and interaction terms 
were quantitatively evaluated using mathematical model. Dissolution data were fitted to 
zero order, first order, and Higuchi’s release kinetics to evaluate kinetic data. According 
to Korsmeyer's equation drug release followed both diffusion and erosion mechanism in 
all cases. Drug release was different from three fillers (microcrystalline cellulose, lactose 
and dibasic calcium phosphate). 
 
33. Sandeep Gummudavelly et al floating matrix tablets of Alfuzosin hydrochloride were 
developed to prolong gastric residence time. Alfuzosin hydrochloride was chosen as a 
model drug because it is poorly absorbed from the lower gastrointestinal tract. The tablets 
were prepared by direct compression and melt granulation technique, using polymers 
such as hydroxy propyl methyl cellulose K15M, sodium carboxy methyl cellulose, 
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compritol 888 ATO and either alone or in combination, and other standard excipients. 
Tablets were evaluated for physical characteristics hardness, % friability, floating 
capacity, weight variation, content uniformity, in-vitro release characteristics for 12 hours 
and in-vivo gastic retention time. In-vitro release mechanism was evaluated by linear 
regression analysis. The calculated regression coefficients value of higuchi and 
koresemayer (0.998, n value 0.520) for optimized formulation F2 and the drug release 
mechanism was found to be non-ficikian diffusion. No drug-polymer interaction was 
observed by Fourier Transform Infrared Spectra Analysis. In-vivo studies showed that the 
tablets retained in stomach for 6hours. It was concluded that, HPMC K15M alone 
retarded the drug release for highly water soluble drug (Alfuzosin hydrochloride) for a 
period of 12 hours. 
34.  Sreenivasa Reddy et al alfuzosin Hydrochloride extended release tablets ere prepared 
by wet granulation method by using natural and synthetic polymers Guar gum, Eudragit 
RLPO and Hypromellose (Methocel K100M). The present study was to develop stable 
and robust formulation of Alfuzosin Hydrochloride ER tablets 10mg. The formulation 
containing binary mixer of Hypromellose at 31.0 % and Guar gum at 11.0 % were 
evaluated for various physicochemical parameters by official procedures showed 
consistent results. The in-vitro release study of tablets was carried out in 0.01N HCL for 
20 hours. A time (hr.) interval 1, 2, 6, 12, and 20 has showed the best formulation 
releases when compared with the reference product. Both the diffusion and erosion 
mechanisms were responsible for drug release as shown by the power law. Dissolution 
data were fitted to zero order, first order, Higuchi's, Peppas & Korsmeyer,Hixson 
Crowell, Weibull and Baker Lonsdale release kinetics to evaluate kinetic data. The main 
effect and interaction terms were quantitatively evaluated using mathematical model. 
Hence the gradual release of Alfuzosin Hydrochloride over a prolonged time period of 20 
hr. which indicates the usefulness of the formulation for once daily dosage form. 
Optimized formulation was found stable during accelerated stability study for 3 months at 
40°C± 2°&75%±5 % RH.  
35. Prashant Khemariya et al the objective of this research work was to formulate and 
evaluate the floating drug delivery system containing Ofloxacin as a model drug and to 
optimize the drug release profile. Ofloxacin is a slightly water-soluble drug and having 
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absorption only in upper part of GI tract (up to jejunum). Ofloxacin tablets were prepared 
by dry granulation technique which containing HPMC K100M, xanthan gum, carbopol 
934P, PVP K30, MCC, lactose, aerosil, and gas generating agent such as sodium 
bicarbonate were taken as independent variables. The compressed matrix tablets were 
evaluated for various parameters like hardness, friability, weight variation, uniformity of 
drug. Result shows the drug content was uniform in all the formulations of the prepared 
tablets. In vitro drug release pattern was evaluated by using USP-I (Basket) apparatus 
containing 0.1 N HCl and Simulated gastric fluid. The optimized formulation containing 
Ofloxacin-800 mg, HPMC K-15- M-5 mg, xanthan gum-12.5 to 24 mg, aerosol-1 mg, 
Mg Stearate- 9+4 mg and sodium bicarbonate- 80 mg has displayed almost zero order 
release kinetics with a floating lag time of between 10 sec. to 56 sec. The effect of 
formulation variables namely, different excipients, different polymers, and concentration 
of polymer were studied. 
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AIM AND OBJECTIVE 
 
The alfuzosin of the present investigation is designed to retain in the stomach and deliver 
the drug alfuzosin for longer periods of time. The developed floating provides increased 
absorption of the alfuzosin at a rate such that effective plasma levels can be achieved and 
maintained for a prolonged duration.  
 
The tablets were found to be floating immediately upon contact with the release medium 
showing no lag times in floating behavior because of the low density material. Extended floating 
times are achieved due to the air entrapped within the drug particles. This system provides more 
reliable retention for prolonged period of time compared to the other gastric retention systems. 
 
Floating of alfuzosin was formulated with HPMC to retain the tablet dosage form in the 
stomach and to release the drug in a controlled manner for increasing the oral bioavailability of 
the alfuzosin. In the present work direct compression method were used to prepare floating 
matrix tablets of alfuzosin. 
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PLAN OF WORK 
 Literature Survey. 
 Preformulation Studies 
1) Bulk density 
2) True density  
3) Carrs’s index  
4) Hausners ratio 
5) Angle of repose 
6) Hardness 
7) Friability 
8) Thickness 
9) Log Float time 
10) Bouncy time 
11) Content uniformity 
 Selection of Excipients.  
1) Hydroxy Propyl methylcellulose 
2) Carbopol940p 
 Compatibility tests. 
1) FT IR 
 Prototype Formulation (Lab Scale Development). 
 Preparation of granules by direct compression method. 
 The best formulation was selected based on available Preformulation formulation. 
Studies. 
 To carry out the Invitro release studies for a period of 12hours. 
 Stability studies were carried out as per the ICH guidelines for a period of 90days. 
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DRUG PROFILE 
 Alfuzosin  
 
Introduction: 
1.  Drug Name: Alfuzosin 
2. Mechanism of Action: Alfuzosin is a non-subtype specific alpha(1)-adrenergic 
blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower 
urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle 
in the bladder neck and prostate, resulting in the improvement in urine flow and a 
reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the 
vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and 
norepinephrine), resulting in peripheral vasodilation 
3. Dosage: 10mg ER tablets. 
4. Uses:  
Benign Prostatic Hyperplasia (BPH) 
Reduction of urinary obstruction and relief of associated manifestations (e.g., hesitancy, 
interrupted or weak stream, sensation of incomplete bladder emptying or straining, 
urgency, nocturia) in patients with symptomatic BPH. 
 Although drug therapy usually is not as effective as surgical therapy, it may 
provide adequate symptomatic relief with fewer and less serious adverse effects 
compared with surgery. 
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 May consider combined therapy with a α1-adrenergic blocker and 5α-reductase 
inhibitor for men with bothersome moderate to severe BPH and demonstrable prostatic 
enlargement.
 
Has been more effective than therapy with either drug alone in preventing 
long-term BPH symptom progression.
 
Men at risk for BPH progression are most likely to 
benefit from combination therapy. 
Physicochemical Properties: 
1. Description: Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic 
blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the 
muscles in the prostate and bladder neck, making it easier to urinate. 
2. IUPAC Name: N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-
l)(methyl)amino]propyl}oxolane-2-carboxamide 
3. Molecular Formula: C19H27N5O44. Molecular Weight: Average: 389.4488 
4. Monoisotopic: 389.206304377 
5. Solubility: solubility: H2O: soluble0.3 mg/mL DMSO: soluble18 mg/mL Ethanol: 
 soluble3.4 mg/mL. 
6. Physical Form: White powder. 
7. Melting point: 225oC 
8. Stability: 40 days 
9. Categories: Antihypertensive Agents Adrenergic alpha-Antagonists 
Pharmacokinetic Properties: 
1. Half life (t1/2): 10 hours (biological). 
2. Shelf-Life: 36 months. 
3.  Bioavailability: 50 
4.  PH: 2.2-2. 
5.  PKa : 0 
6. Protein Binding: 82-90% 
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7.  Route of Metabolism: Hepatic. Alfuzosin undergoes extensive metabolism by the liver, 
with only 11% of the administered dose excreted unchanged in the urine. Alfuzosin is 
metabolized by three metabolic pathways: oxidation, O-demethylations, and N-
dealkylation. The metabolites are not pharmacologically active. CYP3A4 is the principal 
hepatic enzyme isoform involved in its metabolism. 
8. Route of Elimination: Following oral administration of 14C-labeled alfuzosin solution, 
the recovery of radioactivity after 7 days (expressed as a percentage of the administered 
dose) was 69% in feces and 24% in urine. 
9. Volume of distribution:  3.2 L/kg [healthy male middle-aged volunteers] 
Food Interactions   
Take after a meal (always the same meal), product bioavailability is reduced when taken on an 
empty stomach. 
DRUG INTERACTIONS 
Conivaptan CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin. 
Concomitant use of alfuzosin with a strong CYP3A4 inhibitor is a listed contraindication 
according to alfuzosin prescribing information. 
 Itraconazole the antifungal increases the effect of alfuzosin 
Ketoconazole the antifungal increases the effect of alfuzosin  
Ritonavir  increases the effect/toxicity of alfuzosin  
Tadalafil may enhance the hypotensive effect of Alfusozin. Monitor for hypotension during 
concomitant therapy.  
Tamsulosin Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Alfuzosin, may 
result in additive antihypertensive effects. Combination therapy is not recommended. 
Telithromycin Telithromycin may reduce clearance of Alfuzosin. Consider alternate therapy. 
Terazosin Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension 
and syncope. Concomitant therapy should be avoided.  
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Vardenafil Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, 
Alfuzosin, may occur. Monitor for hypotension during concomitant therapy. 
Voriconazole a strong CYP3A4 inhibitor, may increase the serum concentration of alfuzosin by 
decreasing its metabolism. Use of alfuzosin with strong CYP3A4 inhibitors is contraindicated by 
the manufacturer. 
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POLYMER PROFILE 
Hypromellose 
1. Nonproprietary Names 
BP: Hypromellose 
JP: Hypromellose 
PhEur: Hypromellose 
USP: Hypromellose 
 
2. Synonyms 
Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; hypromellosum; Methocel; 
methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; MHPC; 
Pharmacoat; Tylopur; Tylose MO. 
 
3. Chemical Name and CAS Registry Number :Cellulose hydroxypropyl methyl ether [9004-
65-3] 
 
4. Empirical Formula and Molecular Weight 
The PhEur 6.3 describes hypromellose as a partlyO-methylated and O-(2-hydroxypropylated) 
cellulose. It is available in several grades that vary in viscosity and extent of substitution. Grades 
may be distinguished by appending a number indicative of the apparent viscosity, in mPa s, of a 
2% w/w aqueous solution at 208C. Hypromellose defined in the USP 32 specifies the 
substitution type by appending a four-digit number to the nonproprietary name: e.g. 
hypromellose 1828. The first two digits refer to the approximate percentage content of the 
methoxy group (OCH3). The second two digits refer to the approximate percentage content of 
the hydroxypropoxy group (OCH2CH(OH)CH3), calculated on a dried basis. It contains 
methoxy and hydroxypropoxy groups conforming to the limits for the various types of 
hypromellose;Molecular weight is approximately 10 000–1 500 000. 
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5. Structural Formula 
 
 
Where R is H, CH3, or CH3CH(OH)CH2 
 
6. Functional Category 
 
 Bioadhesive material; coating agent; controlled-release agent;dispersing agent; 
dissolution enhancer; emulsifying agent; emulsion stabilizer; extended-release agent; film-
forming agent; foaming agent; granulation aid; modified-release agent; mucoadhesive; release-
modifying agent; solubilizing agent; stabilizing agent; suspending agent; sustained-release agent; 
tablet binder; thickening 
agent; viscosity-increasing agent.  
 
7 Applications in Pharmaceutical Formulation or Technology 
  
 Hypromellose is widely used in oral, ophthalmic, nasal, and topical pharmaceutical 
formulations.In oral products, hypromellose is primarily used as a tablet binder,(1) in film-
coating,(2–7) and as a matrix for use in extendedrelease tablet formulations.(8–12) 
Concentrations between 2% and 5% w/w may be used as a binder in either wet- or dry-
granulation processes. High-viscosity grades may be used to retard the release of drugs from a 
matrix at levels of 10–80% w/w in tablets and capsules. Hypromellose is also used in liquid oral 
dosage forms as a suspending and/or thickening agent at concentrations ranging from 0.25–
5.0%.Depending upon the viscosity grade, concentrations of 2–20% w/w are used for film-
forming solutions to film-coat  tablets.Lowerviscosity grades are used in aqueous film-coating 
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solutions, while Hypromellose higher-viscosity grades are used with organic solvents. Examples 
of film-coating materials that are commercially available include AnyCoat C, Spectracel, 
Pharmacoat, and the Methocel E Premium LV series.Hypromellose is also used as a suspending 
and thickening agent in topical formulations. Compared with methylcellulose, hypromellose 
produces aqueous solutions of greater clarity, with fewer undissolved fibers present, and is 
therefore preferred in formulations for ophthalmic use. Hypromellose at concentrations  between 
0.45–1.0% w/w may be added as a thickening agent to vehicles for eye drops and artificial tear 
solutions. It is also used  commercially in liquid nasal formulations at a concentration of 0.1%. 
Hypromellose is used as an emulsifier, suspending agent, and stabilizing agent in topical gels and 
ointments. As a protective colloid, it can prevent droplets and particles from coalescing or 
agglomerating, thus inhibiting the formation of sediments. In addition, hypromellose is used in 
the manufacture of capsules, as an adhesive in plastic bandages, and as a wetting agent for hard 
contact lenses. It is also widely used in cosmetics and food products.  
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or granular powder. 
SEM 1: Excipient: Methocel E5; manufacturer: Dow Wolff Cellulosics; magnification: 200_; 
voltage: 3 kV. 
 
 
SEM 2: Excipient: Methocel K4M; manufacturer: Dow Wolff Cellulosics; 
magnification: 500_; voltage: 3 kV. 
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9. Typical Properties 
 
Acidity/alkalinity pH = 5.0–8.0 for a 2% w/w aqueous solution. 
Ash-41.5% 
Autoignition temperature- 360
o
C 
Density (bulk)-0.341 g/cm3 
Density (tapped)- 0.557 g/cm3 
Density (true)-1.326 g/cm3 
Melting point  Browns at 190–2008C; chars at 225–2308C. Glass 
Transition Temperature is 170–1808C. 
Moisture content Hypromellose absorbs moisture from the atmosphere; the amount of water 
absorbed depends upon the initial 
moisture content and the temperature and relative humidity of the surrounding air.  
Solubility Soluble in cold water, forming a viscous colloidal solution; practically insoluble in hot 
water, chloroform, ethanol 
(95%), and ether, but soluble in mixtures of ethanol and dichloromethane, mixtures of methanol 
and dichloromethane, and mixtures of water and alcohol. Certain grades of hypromellose are 
soluble in aqueous acetone solutions, mixtures of dichloromethane and propan-2-ol, and other 
organic solvents. Some grades are swellable in ethanol. 
Specific gravity 1.26 
Viscosity (dynamic) 
A wide range of viscosity types are commercially available. Aqueous solutions are most 
commonly prepared, although hypromellose may also be dissolved in aqueous alcohols such as 
ethanol and propan-2-ol provided the alcohol content is less than 50% w/w. Dichloromethane 
and ethanol mixtures may also be used to prepare viscous hypromellose solutions. 
Solutions prepared using organic solvents tend to be more viscous; increasing concentration also 
produces more viscous solutions 
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10 Stability and Storage Conditions 
 
 Hypromellose powder is a stable material, although it is hygroscopic after drying. 
Solutions are stable at pH 3–11. Hypromellose undergoes a reversible sol–gel transformation 
upon heating and cooling, respectively. The gelation temperature is 50–908C, depending upon 
the grade and concentration of material. For temperatures below the gelation temperature, 
viscosity of the solution decreases as temperature is increased. Beyond the gelation temperature, 
viscosity increases as temperature is increased.  
  
 Aqueous solutions are comparatively enzyme-resistant, providing good viscosity stability 
during long-term storage.(15) However, aqueous solutions are liable to microbial spoilage and 
should be preserved with an antimicrobial preservative: when hypromellose is used as a 
viscosity-increasing agent in ophthalmic solutions, benzalkonium chloride is commonly used as 
the preservative. Aqueous solutions may also be sterilized by autoclaving; the coagulated 
polymer must be redispersed on cooling by shaking. Hypromellose powder should be stored in a 
well-closed container, in a cool, dry place. 
 
11 Incompatibilities 
 
 Hypromellose is incompatible with some oxidizing agents. Since it is nonionic, 
hypromellose will not complex with metallic salts or ionic organics to form insoluble 
precipitates. 
 
12 Method of Manufacture 
 
 A purified form of cellulose, obtained from cotton linters or wood pulp, is reacted with 
sodium hydroxide solution to produce a swollen alkali cellulose that is chemically more reactive 
than untreated cellulose. The alkali cellulose is then treated with chloromethane and propylene 
oxide to produce methyl hydroxypropyl ethers of cellulose. The fibrous reaction product is then 
purified and ground to a fine, uniform powder or granules. Hypromellose can then be exposed to 
anhydrous hydrogen chloride to induce depolymerization, thus producing low viscosity grades.  
13 Safety 
 
 Hypromellose is widely used as an excipient in oral, opthalmic, nasal, and topical 
pharmaceutical formulations. It is also used extensively in cosmetics and food products. 
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Hypromellose is generally regarded as a nontoxic and nonirritating material, although excessive 
oral consumption may have a laxative effect.The WHO has not specified an acceptable daily 
intake for hypromellose since the levels consumed were not considered to represent a hazard to 
health. In fact, high dosages of hypromellose are being investigated for treating various 
metabolic syndromes. 
14 Handling Precautions 
  
 Observe normal precautions appropriate to the circumstances and quantity of material 
handled. Hypromellose dust may be irritating to the eyes, so eye protection is recommended. 
Excessive dust generation should be avoided to minimize the risks of explosion. Hypromellose is 
combustible. 
 
Nominal viscosity (mPa s) 
Methocel K3 Premium LV  
Methocel K100 Premium LVEP  
Methocel K4M Premium  
Methocel K15M Premium  
Methocel K100M Premium  
Methocel E3 Premium LV  
Methocel E5 Premium LV  
Methocel E6 Premium LV  
Methocel E15 Premium LV  
Methocel E50 Premium LV  
Methocel E4M Premium  
Methocel E10M Premium CR  
Methocel F50 Premium  
Methocel F4M Premium  
Metolose 60SH 2910 50, 4000, 10 000 
Metolose 65SH 2906 50, 400, 1500, 4000 
Metolose 90SH 2208 100, 400, 4000, 15 000 
H 
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17 Related Substances 
  
 Ethylcellulose; hydroxyethyl cellulose; hydroxyethylmethyl cellulose; hydroxypropyl 
cellulose; hypromellose acetate succinate; hypromellose phthalate; methylcellulose. 
 
CARBOMER 
 
1 Nonproprietary Names 
BP: Carbomers 
PhEur: Carbomers 
USP-NF: Carbomer 
 
2 Synonyms 
Acrypol; Acritamer; acrylic acid polymer; carbomera; Carbopol; 
carboxy polymethylene; polyacrylic acid; carboxyvinyl polymer; 
Pemulen; Tego Carbomer. 
 
3 Chemical Name and CAS Registry Number 
Carbomer [9003-01-4] 
Note that alternative CAS registry numbers have been used for 
carbomer 934 ([9007-16-3]), 940 ([9007-17-4]) and 941 ([9062- 
04-08]). The CAS registry number [9007-20-9] has also been used 
for carbomer. 
 
4 Empirical Formula and Molecular Weight 
Carbomers are synthetic high-molecular-weight polymers of acrylic acid that are crosslinked 
with either allyl sucrose or allyl ethers of pentaerythritol. They contain between 52% and 68% of 
carboxylic acid (COOH) groups calculated on the dry basis. The BP 2009 and PhEur 6.4 have a 
single monograph describing carbomer; the USP32–NF27 contains several monographs 
escribing individual carbomer grades that vary in aqueous viscosity, polymer type, and 
polymerization solvent. The molecular weight of carbomer is theoretically estimated at 7 _ 105 
to 4 _ 109. In an effort to measure the molecular weight between crosslinks, MC, researchers 
have extended the network theory of elasticity to swollen gels and have utilized the inverse 
relationship between the elastic modulus and MC.(1–3) Estimated MC values of 237 600 g/mol 
for Carbopol 941 and of 104 400 g/mol for Carbopol 940 have been reported. In general, 
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carbomer polymers with lower viscosity and lower rigidity will have higher MC values. 
Conversely, higher-viscosity,  more rigid carbomer polymers will have lower MC values. 
 
5 Structural Formula 
Carbomer polymers are formed from repeating units of acrylic acid. The monomer unit is shown 
above. The polymer chains are 
crosslinked with allyl sucrose or allyl pentaerythritol.  
 
6 Functional Category 
Bioadhesive material; controlled-release agent; emulsifying agent;emulsion stabilizer; rheology 
modifier; stabilizing agent; suspending agent; tablet binder. 
 
7 Applications in Pharmaceutical Formulation or Technology 
Carbomers are used in liquid or semisolid pharmaceutical formulations as rheology modifiers. 
Formulations include creams, gels, lotions and ointments for use in ophthalmic, rectal,topical  
and vaginal preparations. Carbomer grades with residual benzene  content greater than 2 ppm do 
not meet the specifications of the PhEur 6.4 monograph. However, carbomer having low 
residuals of other solvents than the ICH-defined ‘Class I OVI solvents’ may be used in Europe. 
Carbomer having low residuals of ethyl acetate, such as Carbopol 971P NF or Carbopol 974P 
NF, may be used in oral preparations, in suspensions, capsules or tablets.(23–35) In tablet 
formulations, carbomers are used as controlled release agents and/or as binders. In contrast to 
linear polymers, higher viscosity does not result in slower drug release with carbomers. Lightly 
crosslinked carbomers (lower viscosity) are generally more efficient in controlling drug release 
than highly crosslinked carbomers (higher viscosity). In wet granulation processes, water, 
solvents or their mixtures can be used as the granulating fluid. The tackiness of the wet mass 
may be reduced by including talc in the formulation or by adding certain cationic species to the 
granulating fluid. However, the presence of cationic salts may accelerate drug release rates and 
reduce bioadhesive properties. Carbomer polymers have also been investigated in the preparation 
of sustained-release matrix beads, as enzyme inhibitors of intestinal proteases in peptide-
containing dosage forms, as a bioadhesive for a cervical patch and for intranasally administered 
microspheres, in  magnetic granules for site-specific drug delivery to the esophagus, and in oral 
mucoadhesive controlled drug delivery systems. Carbomers copolymers are also employed as 
emulsifying agents in the preparation of oil-in-water emulsions for external administration. 
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Carbomer 951 has been investigated as a viscosity-increasing aid in the preparation of multiple 
emulsion microspheres. Carbomers are also used in cosmetics. Therapeutically, carbomer 
formulations have proved efficacious in improving  symptoms of moderate-to-severe dry eye 
syndrome. 
Table I: Uses of carbomers. 
Use Concentration (%) 
Emulsifying agent          0.1–0.5 
Gelling agent                   0.5–2.0 
Suspending agent               0.5–1.0 
Tablet binder                          0.75–3.0 
Controlled-release agent     5.0–30.0 
 
8 Description 
 
 Carbomers are white-colored, ‘fluffy’, acidic, hygroscopic powders with a characteristic 
slight odor. A granular carbomer is also 
available (Carbopol 71G). 
SEM 1: Excipient: Carbopol 971P; manufacturer: Lubrizol Advanced 
 
Materials, Inc.; magnification: 2000_; voltage: 25 kV 
.  
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SEM 2: Excipient: Carbopol 971P; manufacturer: Lubrizol Advanced 
Materials, Inc.; magnification: 6000_; voltage: 25 kV. 
 
 
 
Aqueous viscosity (mPa s) 300–115 000  
Carbomer 934 (0.5% w/v) — 30 500–39 400 
Carbomer 934P (0.5% w/v) — 29 400–39 400 
Carbomer 940 (0.5% w/v) — 40 000–60 000 
Carbomer 941 (0.5% w/v) — 4 000–11 000 
Carbomer 1342 (1.0% w/v) — 9 500–26 500 
Carbomer copolymer (1% w/v) 
Type A — 4 500–13 500 
Type B — 10 000–29 000 
Type C — 25 000–45 000 
Carbomer homopolymer (0.5% w/v) 
Type A — 4 000–11 000 
Type B — 25 000–45 000 
Type C — 40 000–60 000 
Carbomer interpolymer 
Type A (0.5% w/v) — 45 000–65 000 
Type B (1% w/v) — 47 000–77 000 
Type C (0.5% w/v) — 8 500–16 500 
Loss on drying 43.0% 42.0% 
Sulfated ash 44.0% — 
Residue on ignition — 44.0%(a) 
Heavy metals 420 ppm 40.002% 
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Benzene 42 ppm þ 
Carbomer 934 — 40.5% 
Carbomer 934P — 40.01% 
Carbomer 940 — 40.5% 
Carbomer 941 — 40.5% 
Carbomer 1342 — 40.2% 
Carbomer copolymer — 40.0002% 
Carbomer homopolymer — 40.0002% 
Carbomer interpolymer — 40.0002% 
Free acrylic acid 40.25% 40.25%(b) 
Ethylacetate — þ 
Carbomer copolymer — 40.5% 
Carbomer homopolymer — 40.5% 
Carbomer interpolymer — 40.35% 
Cyclohexane — þ 
Carbomer copolymer — 40.3% 
Carbomer homopolymer — 40.3% 
Carbomer interpolymer — 40.15% 
 
9 Typical Properties 
Acidity/alkalinity 
pH = 2.5–4.0 for a 0.2% w/v aqueous dispersion; pH = 2.5–3.0 for Acrypol 1% w/v aqueous 
dispersion. 
Density (bulk) 0.2 g/cm3 (powder); 0.4 g/cm3 (granular).  
Density (tapped) 0.3 g/cm3 (powder); 0.4 g/cm3 (granular). 
Dissociation constant pKa = 6.0_0.5 
Glass transition temperature 100–1058C 
Melting point Decomposition occurs within 30 minutes at 2608C. 
Moisture content Typical water content is up to 2% w/w. However, carbomers are hygroscopic 
and a typical equilibrium 
moisture content at 258C and 50% relative humidity is 8–10% w/w. The moisture content of a 
carbomer does not affect its 
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thickening efficiency, but an increase in the moisture content makes the carbomer more difficult 
to handle because it is less readily dispersed. 
 
10 Stability and Storage Conditions 
Carbomers are stable, hygroscopic materials that may be heated at temperatures below 1048C for 
up to 2 hours without affecting their thickening efficiency. However, exposure to excessive 
temperatures can result in discoloration and reduced stability. Complete decomposition occurs 
with heating for 30 minutes at 2608C. Dry powder forms of carbomer do not support the growth 
of molds and fungi. In contrast, microorganisms grow well in unpreserved aqueous dispersions, 
and therefore an antimicrobial preservative such as 0.1% w/v chlorocresol, 0.18% w/v 
methylparaben–0.02% w/v propylparaben, or 0.1% w/v thimerosal should be added. The 
addition of certain antimicrobials, such as benzalkonium chloride or sodium benzoate, in high 
concentrations (0.1% w/v) can cause cloudiness and a reduction in viscosity of carbomer 
dispersions. Aqueous gels may be sterilized by autoclaving(7) with minimal changes in viscosity 
or pH, provided care is taken to exclude oxygen from the system, or by gamma irradiation, 
although this technique may increase the viscosity of the formulation.(54,55) At room 
temperature, carbomer dispersions maintain their viscosity during storage for prolonged periods. 
Similarly, dispersion viscosity is maintained, or only slightly reduced, at elevated storage 
temperatures if an antioxidant is included in the formulation or if the dispersion is stored 
protected from light. Exposure to light causes oxidation that is reflected in a decrease in 
dispersion viscosity. Stability to light may be improved by the addition of 0.05–0.1% w/v of a 
water-soluble UV absorber such as benzophenone-2 or benzophenone-4 in combination with 
0.05–0.1% w/v edetic acid. Carbomer powder should be stored in an airtight, corrosionresistant 
container and protected from moisture. The use of glass, plastic, or resin-lined containers is 
recommended for the storage of formulations containing carbomer.  
 
11 Incompatibilities 
 Carbomers are discolored by resorcinol and are incompatible with phenol, cationic 
polymers, strong acids, and high levels of electrolytes. Certain antimicrobial adjuvants should 
also be avoided or used at low levels, see Section 11. Trace levels of iron and other transition 
metals can catalytically degrade carbomer dispersions. Certain amino-functional actives form 
complexes with carbomer; often this can be prevented by adjusting the pH of the dispersion 
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and/or the solubility parameter by using appropriate alcohols and polyols. Carbomers also form 
pH-dependent complexes with certain polymeric excipients. Adjustment of pH and/or solubility 
parameter can also work in this situation. 
 
12 Handling Precautions 
 Observe normal precautions appropriate to the circumstances and quantity of material 
handled. Excessive dust generation should be minimized to avoid the risk of explosion (lowest 
explosive concentration is 130 g/m3). Carbomer dust is irritating to the eyes, mucous 
membranes, and respiratory tract. In the event of eye contact with carbomer dust, saline should 
be used for irrigation purposes. Gloves, eye protection, and a dust respirator are recommended 
during handling. A solution of electrolytes (sodium chloride) is recommended for cleaning 
equipment after processing carbomers. 
13 Related Substances 
Polycarbophil. 
CARBOXYMETHYLCELLULOSE SODIUM 
1 Nonproprietary Names 
BP: Carmellose Sodium 
JP: Carmellose Sodium 
PhEur: Carmellose Sodium 
USP: Carboxymethylcellulose Sodium 
[[[2 Synonyms 
Akucell; Aqualon CMC; Aquasorb; Blanose; Carbose D; carmellosum natricum; Cel-O-Brandt; 
cellulose gum; Cethylose; CMC sodium; E466; Finnfix; Glykocellan; Nymcel ZSB; SCMC; 
sodium carboxymethylcellulose; sodium cellulose glycolate; Sunrose; Tylose CB; Tylose MGA; 
Walocel C; Xylo-Mucine. 
3 Chemical Name and CAS Registry Number 
Cellulose, carboxymethyl ether, sodium salt [9004-32-4] 
4 Empirical Formula and Molecular Weight The USP 32 describes carboxymethylcellulose 
sodium as the sodium salt of a polycarboxymethyl ether of cellulose.  
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5 Functional Category 
Coating agent; stabilizing agent; suspending agent; tablet and capsule disintegrant; tablet binder; 
viscosity-increasing agent; water-absorbing agent. 
6 Applications in Pharmaceutical Formulation or Technology 
 Carboxymethylcellulose sodium is widely used in oral and topical pharmaceutical 
formulations, primarily for its viscosity-increasing properties. Viscous aqueous solutions are 
used to suspend powders intended for either topical application or oral and parenteral 
administration. Carboxymethylcellulose sodium may also be used as a tablet binder and 
disintegrant, and to stabilize emulsions.Higher concentrations, usually 3–6%, of the medium-
viscosity grade are used to produce gels that can be used as the base for applications and pastes; 
glycols are often included in such gels to prevent them drying out. Carboxymethylcellulose 
sodium is also used in self-adhesive ostomy, wound care, and dermatological patches as a muco-
adhesive and to absorb wound exudate or transepidermal water and sweat. This muco-adhesive 
property is used in products designed to prevent post-surgical tissue adhesions; and to localize 
and modify the release kinetics of active ingredients applied to mucous membranes; and for bone 
repair.Encapsulation with carboxymethylcellulose sodium can affect drug protection and 
delivery. There have also been reports of its use as cyto-protective agent.Carboxymethylcellulose 
sodium is also used in cosmetics, toiletries, surgical prosthetics, and incontinence, personal 
hygiene, and food products.  
TableI: Uses of carboxymethylcellulose sodium. 
Uses Concentration (%) 
Emulsifying Agent 0.25-1.0 
Gel-forming agent 3-6 
Injections 0.05-0.75 
Oral solutions 0.1-1.0 
Tablet binder 1-6 
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7 Description 
Carboxymethylcellulose sodium occurs as a white to almost white, odorless, tasteless, granular 
powder. It is hygroscopic after drying. 
8 Typical Properties 
Density (bulk) 0.52 g/cm3 
Density (tapped) 0.78 g/cm3 
Dissociation constant pKa = 4.30 
 Melting point Browns at approximately 227
o
C, and chars at approximately 
252
o
C.Moisture content, typically contains less than 10% water. However, 
carboxymethylcellulose sodium is hygroscopic and absorbs significant amounts of water at 
temperatures up to 37
o
C at relative humidities of about 80%. 
 Solubility Practically insoluble in acetone, ethanol (95%), ether, and toluene. Easily 
dispersed in water at all temperatures,forming clear, colloidal solutions. The aqueous solubility 
varies with the degree of substitution (DS).  
 Viscosity Various grades of carboxymethylcellulose sodium are commercially available 
that have differing aqueous viscosities; Aqueous 1% w/v solutions with viscosities of 5–2000 
mPa s (5–2000 cP) may be obtained. An increase in concentration results in an increase in 
aqueous solution viscosity.Prolonged heating at high temperatures will depolymerize the gum 
and permanently decrease the viscosity. The viscosity of sodium carboxymethylcellulose 
solutions is fairly stable over a pH range of 4–10. The optimum pH range is neutral.  
9  Stability and Storage Conditions 
 Carboxymethylcellulose sodium is a stable, though hygroscopic material. Under high-
humidity conditions, carboxymethylcellulose sodium can absorb a large quantity (>50%) of 
water. In tablets, this has been associated with a decrease in tablet hardness and an increase in 
disintegration time. 
 Aqueous solutions are stable at pH 2–10; precipitation can occur below pH 2, and 
solution viscosity decreases rapidly above pH 10. Generally, solutions exhibit maximum 
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viscosity and stability at pH 7–9. Carboxymethylcellulose sodium may be sterilized in the dry 
state by maintaining it at a temperature of 160
o
C for 1 hour. However, this process results in a 
significant decrease in viscosity and some deterioration in the properties of solutions prepared 
from the sterilized material. 
 Aqueous solutions may similarly be sterilized by heating, although this also results in 
some reduction in viscosity. After autoclaving, viscosity is reduced by about 25%, but this 
reduction is less marked than for solutions prepared from material sterilized in the dry state. The 
extent of the reduction is dependent on the molecular weight and degree of substitution; higher 
molecular weight grades generally undergo a greater percentage reduction in 
viscosity.Sterilization of solutions by gamma irradiation also results in a reduction in viscosity. 
Aqueous solutions stored for prolonged periods should contain an antimicrobial preservative.The 
bulk material should be stored in a well-closed container in a cool, dry place. 
11 Incompatibilities 
 Carboxymethylcellulose sodium is incompatible with strongly acidic solutions and with 
the soluble salts of iron and some other metals, such as aluminum, mercury, and zinc. It is also 
incompatible with xanthan gum. Precipitation may occur at pH < 2, and also when it is mixed 
with ethanol (95%). Carboxymethylcellulose sodium forms complex coacervates with gelatin 
and pectin. It also forms a complex with collagen and is capable of precipitating certain 
positively charged proteins.  
12 Related Substances 
Carboxymethylcellulose calcium. 
SODIUM BICARBONATE : 
 Structure: 
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 Non-proprietary Names 
 BP: Sodium bicarbonate. 
 Ph. Eur.: Natrii hydrogenocarbonas. 
 USP: Sodium bicarbonate. 
 Synonyms: Baking soda; E500; monosodium carbonate; sodium acid, 
 Carbonate: sodium hydrogen carbonate. 
 Chemical Name: Carbonic acid monosodium salt. 
 Empirical Formula: NaHCO3 
 Molecular Weight: 84.01 
 Functional Category: Alkalizing agent; therapeutic agent. 
 Description: Sodium bicarbonate occurs as an odorless, white crystalline powder with a 
saline, slightly alkaline taste. The crystal structure is monoclinic prisms. Grades with 
different particle sizes, from a fine powder to free flowing uniform granules, are 
commercially available. 
 Properties: 
 Density: 2.159 g/cm3 
 Solubility: Practically insoluble in Ethanol (95%) and Ether. freely Soluble in water. 
 Stability and Storage condition: Sodium bicarbonate is stable in dry air but slowly 
decomposes in moist air should therefore be stored in a well-closed container in a cool, 
dry, place. 
 Safety: Sodium bicarbonate is metabolized to the sodium cation, which is eliminating 
from the body by renal excretion, and the bicarbonate anion, which becomes part of the 
body’s store. Any carbon dioxide is eliminated via the lungs. Administration of excessive 
amounts of sodium bicarbonate may thus disturb the body’s electrolyte balance leading to 
metabolic alkalosis or possibly sodium overload potentially serious consequences. Orally 
ingested sodium bicarbonate neutralizes gastric acid with the evolution of carbon dioxide 
and may cause stomach cramps and flatulence. When used as excipients, sodium 
bicarbonate is generally regarded as an essentially nontoxic and nonirritant material. 
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MICROCRYSTALLINE CELLULOSE
 
Description
 
Microcrystalline cellulose is purified, partially depolymerized cellulose that occurs as a 
white, odorless, tasteless, crystalline powder composed of porous particles. It is commercially 
available in different particle size Stretching and moisture grades that have different properties 
and applications. 
Formula 
  (C 6H10 O5)n 
Molecular weight:  
  n~220 
Density (bulk):  
  0.32 g/cm
3 
  
Density (tapped): 
   0.45g/cm
3 
Density (true):  
  1.512-1.668 g/cm
3 
Melting point: 
   Chars at 260-270 
0
 C. 
Solubility:  
  
 Slightly soluble in 5% W/V sodium hydroxide solution; practically insoluble in water, 
dilute acids, and most organic solvents. 
 
Application in pharmaceutical Formulation Technology  
 Microcrystalline cellulose is widely used in pharmaceuticals, primarily as binder/diluents 
in oral tablet and capsule formulations where it is used in both wet granulation and direct-
compression process. In addition to its use as a binder /diluents, microcrystalline cellulose also 
has some lubricant and disintegrant properties that make it useful in tableting. 
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Functional Category  
 
 Adsorbent; suspending agent; tablet and capsule diluents; tablet disintegrant. 
Use of Microcrystalline cellulose 
Use Concentration(%) 
Adsorbent 20-90 
Antiadherent 5-20 
Capsule binder/diluents 20-90 
Tablet disintegrant 5-15 
Tablet binder/diluents 20-90 
 
Incompatibilities: 
 
  Microcrystalline cellulose is compatible with strong oxidizing agents. 
Safety 
 Microcrystalline cellulose is widely used in oral pharmaceutical formulations and food 
products and is generally regarded as a nontoxic and nonirritant material. Microcrystalline 
cellulose is not absorbed systemically following oral administration and thus has little toxic 
potential. Consumption of large quantities of cellulose may, however, have a laxative effect, 
although this is unlikely to be a problem when cellulose is used as excipients in pharmaceutical 
formulations. Deliberate abuse of formulation containing cellulose, either by inhalation or 
injection, has resulted in the formulation. 
Magnesium Stearate
 
Chemical structure: 
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Synonyms: HyQual, magnesium octadecanoate, stearic acid magnesium salt. 
Chemical name and CAS registry number: Octadecanoic acid magnesium salt  [557-04- 0]. 
Functional category: Tablet and capsule lubricant.  
 
Applications: It is primarily used as a lubricant in capsule and Tablet manufacture at 
concentrations between 0.25-5.0percent.  
 
Description: It is a fine, white, precipitated or milled, impalpable powder of low bulk density, 
having a faint characteristic odor and taste. The powder is greasy to touch and readily adheres to 
the skin.  
 
Solubility: Practically insoluble in ethanol, ethanol (95%), ether and water, slightly soluble in 
benzene and warm ethanol (95%).  
 
Stability: Magnesium stearate is stable.  
 
Storage conditions: It should be stored in a well-closed container in a cool, dry, place.  
 
Incompatibilities: Incompatible with strong acids, alkalis, iron salts and with strong oxidizing 
materials.  
 
Safety: It is generally regarded as being nontoxic following oral administration. However, oral 
consumption of large quantities may result in some laxative effect or mucosal irritation.  
 
TALC
 18
   
Synonyms: Magsil Osmanthus, Magsil Star, Purtalc, Steatite. 
 
Chemical Name and CAS Registry Number: Talc [14807-96-6]. 
 
Empirical Formula and Molecular Weight: Talc is a purified, hydrated, magnesium silicate, 
approximating to the formula Mg6 (Si2O5)4(OH)4. 
 
Functional category: Glidant, tablet and capsule lubricant, anti- cackling agent.  
 
Applications: It is used as a lubricant in solid dosage forms (1-10%), in topical preparations as 
dusting powder (90-99 %).  
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Description: It is a very fine, white to grayish-white colored, odorless, impalpable, unctuous 
powder. It adheres to the skin, is soft to touch, and free from grittiness 
Solubility: Practically insoluble in dilute acids and alkalies, organic solvents and water.  
 
Stability: Talc is a stable material.  
 
Storage conditions: It should be stored in a well-closed container in a cool, dry, place.  
 
Incompatibilities: Incompatible with quaternary ammonium compounds. 
Safety: Following oral ingestion talc is not absorbed systemically and may thus be regarded as 
an essentially nontoxic material. 
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MATERIALS AND METHODS 
Table no: 2 
    Instrument used 
INSTRUMENTS SUPPLIER/ MANUFACTURER 
Single pan analytical balance Sartorius-Mumbai 
Tapped Density Apparatus Retsec-Mumbai 
    Disintegration Test Apparatus Electro Labs-Mumbai 
Friabiliator Electro Labs –Mumbai 
Dissolution Test Apparatus Lab India –Mumbai 
UV                        Lab India –Mumbai  
Mixer/Granulator Cadmach 
                            FTIR Schimadzu 
                    Mesh # 21,32                         Retsec - Mumbai 
Tablet Punching Machine(10 Station)                                Karnavati 
                  Hot air oven                         Biotechnis India 
                                              
Table no: 3 Material used 
MATERIAL SUPPLIER/ MANUFACTURER 
Quetiapine Fumarate Micro labs 
Lactose Lobachemie pvt. Ltd 
Mannitol SD fine chemicals 
Dicalcium Phosphate                          SD fine chemicals 
Micro Crystalline Cellouse Finar chemicals Ltd 
Magnesium Stearate Finar chemicals Ltd 
Talc SD fine chemicals 
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 STANDARD GRAPH FOR ALFUZOSIN 
 
 The UV scanning of drug sample was carried out using a solution of drug dissolved in 
methanol solution at concentration of 100 µg/ ml. The λ max was observed at 294nm. The 
calibration curve of Alfuzosin was obtained by dissolving the drug in methanol solutions and 
absorbance was measured at 244nm in Methanol solution used as blank. Beer’s law was obeyed 
the concentration range of 5-25 µg in methanol solution. 
 
Method of preparation of pH 6.8 Phosphate buffer solution: 
 224ml of 0.2M NaOH + 500ml of potassium dihydrogen orthophosphate (KH2PO4) and 
makeup the volume to one litres. 
 
How to prepare 0.2M NaOH: Dissolve 8 gm of NaOH in 1000ml of distilled water. 
How to prepare KH2PO4: Dissolve 27.2 gm of KH2PO4 in 1000ml of distilled water.  
PROCEDURE: 
Accurately weighed quantity of Alfuzosin (100mg) was dissolved in methanol and the volume 
made up to 100ml with the same.  
S.S I ⇒ 1000 mcg/ml. 
10ml of Stock solution I was further diluted with 100ml of buffer to get a working standard S.S I 
⇒ 100mcg/ml Aliquots of 5-25µg of stock solution was pipetted into 10ml volumetric flask  and 
diluted up to the volume with buffer. The absorbance was measured at 294nm against reagent 
blank (buffer).As shown in the figure and table .Same procedure was employed to extract the 
standard graph for phosphate buffer 6.8 .As shown in the figure and table. 
PREPARATION OF ALFUZOSIN BY PROCEDURE OF DIRECT COMPRESSION 
Raw material → weighing → screening → Mixing → Compression  
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MASTER FORMULATION FOR ALFUZOSIN 
Table 5          Master formulation 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Alfuzosin hydrochloride 10 10 10 10 10 10 10 10 10 
HPMC K15M 20 30 - - 20 30 - - - 
Sodium CMC - - 20 30 20 30 - 20 30 
Carbopol940 - - - - - - 20 20 30 
MCC 76 66 76 66 56 46 76 56 46 
Sodium Bicarbonate 10 10 10 10 10 10 10 10 10 
Magnesium Sterate 2 2 2 2 2 2 2 2 2 
Talc 2 2 2 2 2 2 2 2 2 
 
EVALUATION PARAMETERS
 
 
Precompression Parameters  
Bulk Density (D
b
):  
It is the ratio of total mass of powder to the bulk volume of powder. It was measured 
by pouring the weighed powder into a measuring cylinder and the volume was noted. It is expressed in 
gm/ml and is given by  
Db = 
0V
M
 
Where, M is the mass of powder, V0 is the bulk volume of the powder 
 Tapped Density (D
T
):  
  It is the ratio of total mass of powder to the tapped volume of powder. The tapped volume was 
measured by tapping the powder to constant volume. It is expressed in gm/ml and is given by  
DT =  
1V
M
    Where, M is the mass of powder, VT is the tapped volume of the powder 
Hausner’s ratio: Hausner’s ratio is the ratio of tapped density to bulk density 
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Hausner’s Ratio   = 
DensityBulk
Density  Tapped
 
Angle of Repose: 
 The frictional forces in a loose powder can be measured by the angle   of repose, θ. This 
is    the maximum angle possible between the surface of a pile of powder and the horizontal 
plane. 
Tan  = tan
-1
 (h/r) 
Where,  is the angle of repose  
H is the height in cms 
R is the radius in cms 
The powder mixture was allowed to flow through the funnel fixed to a stand at definite 
height. The angle of repose was then calculated by measuring the height and radius of the heap 
of powder formed.  
Carr’s Index (I):  
It indicates the ease with which a material can be induced to flow. It is expressed in percentage 
and is given by  
Table    Carr’s Index limit 
Carr’s index (%) Type of flow 
5 – 15 Excellent 
12 – 18 Good 
18 – 23 Fair to passable 
23 – 35 Poor 
35 – 38 Very poor 
> 40 Extremely poor 
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                                  ×100 
 
Post compression Parameters  
Hardness:  
 The hardness of the tablet was determined using a Monsanto hardness tester. It is 
expressed in Kg / cm
2
.  
Friability (F):  
 The friability of the tablet was determined using Roche Friabilator. It is expressed in 
percentage (%). 10 tablets were initially weighed (W
initial
) and transferred into the friabilator. 
The friabilator was operated at 25 rpm for four mins. The tablets were weighed again (W
final
). 
The percentage friability was then calculated. 
Weight Variation:  
 Ten tablets were selected randomly from the lot and weighed individually to check for 
weight variation. IP limit for weight variation in case of tablets weighing more than 325mg is ± 
5%. 
Thickness:  
 The thickness of the tablets was measured by screw gauge. It is expressed in mm.  
 
 Determination of drug content 
 10 tablets were randomly selected from the batch, weighed and powdered. Powder 
equivalent to 100 mg of Alfuzosin was weighed and was diluted with a suitable volume of 0.1M 
sodium hydroxide to produce a solution containing 0.008% w/v of anhydrous Alfuzosin. The 
absorbance of the resulting solution was measured spectrophotometrically at the maximum 
wavelength of about 294 nm, using the solution as a blank which is prepared in the same manner 
omitting the substance being examined. Calculate the content of Alfuzosin from the absorbance 
Tapped density- Bulk density 
Tapped density 
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obtained by repeating the operation using Alfuzosin in place of the substance being examined 
and from the declared content of Alfuzosin.
14
 
 
Invitro dissolution studies: The Invitro dissolution study was carried out in USP dissolution test 
apparatus type 2 (paddle)  
Dissolution Medium: 900ml of simulated gastric fluid  
Temperature: 37 ± 0.5 
o 
C RPM: 50  
Volume withdrawn & replaced: 5 ml every 60 minutes.  Λmax::244 nm. 
  
STABILITY STUDIES  
INTRODUCTION   
 Stability of a drug can be defined as the time from the date of manufacture and the 
packaging of the formulation, until its chemical or biological activity is not less than a 
predetermined level of labeled potency and its physical characteristics have not changed 
appreciably or deleteriously. 
 
OBJECTIVE OF THE STABILITY STUDY  
 
 The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under the influence of a variety of environmental 
factors such as temperature, humidity and light, enabling recommended storage conditions, re-
test periods and shelf-lives. Generally, the observation of the rate at which the product degrades 
under normal room temperature requires a long time. To avoid this undesirable delay, the 
principles of accelerated stability studies are adopted. The International Conference on 
Harmonization (ICH) Guidelines titled “stability testing of New Drug substance and products” 
(QIA) describes the stability test requirements for drug registration applications in the European 
Union, Japan and the United States of America. ICH specifies the length of study and storage 
conditions.  
Long-Term Testing: 25
0 
C ± 2
0 
C / 60% RH ± 5% for 12 Months  
Accelerated Testing: 40
0 
C ± 2
0 
C / 75% RH ± 5% for 6 Months  
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Method  
 
 The selected formulations were packed in amber-colored bottles, which were tightly 
plugged with cotton and capped. They were then stored at 40
0 
C / 75% RH for 3months and 
evaluated for their physical appearance, drug content and drug excipient compatibility at 
specified intervals of time.  
 
 SOME OF THE   PROCESSING PROBLEMS AND THERE REMIDIES  
 Capping: partial or complete separation of top or bottom crowns of tablet main bodey. 
 
Lamination: separation of a tablet into two or more distinct layers. 
 
Table  PROCESSING PROBLEMS AND THERE REMIDIES 
S.No Reasons Remedies 
1 Air entrapment in the tablet among 
granules or among particles. 
By pre-compression, Reducing final 
Compression, Minimizing tableting 
rate. 
2 Deformational properties of formulation 
during and after compression. 
Increasing stress relaxation time 
3 Improper/Deep concave punches 
 
Better to use flat punches 
4 Over dried granules (Due to lack of 
cohesion) 
 
By maintaining moisture levels using 
Hygroscopic materials like MC 
(Methyl Cellulose), Sorbitol, PEG 
4000(Polyethylene glycol) etc. 
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PICKING AND STICKING   
 
Picking:-   
 Adherence of the tablet material from the surface of a tablet by a punch  
Reasons: Because of engraving or embossing or debossing on the punch tips like 
Small enclosed areas in the letters like —A“, B“, D“, 
—O“, Q“etc  
Remedies: Lettering should be designed as large as possible, even the tablet size Can be 
increased by reformulation 
    • Colloidal silica can be added as polishing agent to formula.  
    • Using additional binder to increase cohesiveness of granules and thereby  
     Causing decreased adherence. 
   • Plating of punch faces with a chromium material to obtain smooth face  
     Which is non-adherent 
 
Sticking:-   
 
 Adherence of tablet material to the die walls resulting in chipping of tablet Edges 
producing rough edges and causing the lower punches uneasy to move   resulting in damage of 
cam tracks and punch faces.  
 
Reasons: Presence of low melting point substances in the formula ex. stearic acid,     
PEG (Polyethylene glycol) etc, which gets soften due to compressive heat. 
• Excessive moisture in the granules  
 
Remedies: Partial or complete substitution of low melting point components with  high melting 
point materials in the formula. 
• Proper drying of the granules to remove excessive moisture. 
 
 WEIGHT VARIATION 
 
Granule size and size distribution  
 
Reasons: Proportion of small to large granules influence the die filling capacity and thereby 
results in weight variation of tablets. 
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• If large granules are used to fill small die cavities, even a small difference in granules results 
in high percent weight variation of tablets. 
 
Remedies:   Uniform size distribution (Narrow) and small granular size is preferable. 
 
Poor flow  
Reasons:  Improper design of hopper 
• Poor flow of granules  
• Bridging/arching and rat-holing of granules at the bottom of the hopper 
• Segregation or stratification of parties due to use of flow promotion 
  Devices like vibrators. 
• Surges of excessive flow above the hopper 
 
Remedies:   Flow can be improved by using glidants like talc, colloidal silica etc. 
• By proper design of the hopper 
• By using flow enhancing devices like vibrators  
• By preparing uniform sized and shaped granules   
 
Poor mixing  
Reasons:   Improper mixing of ingredients like glidants and lubricants useful for proper flow 
and punching  
• Insufficient or inadequate time of mixing  
Remedy Proper mixing by maintaining adequate time and using suitable mixer. 
 
Punch variation 
Reason: unequal lengths of lower punches which results in the variation of granular volume 
filled in the die. 
Remedy: proper tooling by using good and uniform sized punches. 
 
Hardness variation 
Reason: 1) due to weight variation in granules filled in the die. 
                2) Space between lower and upper punches. 
Remedy: Proper tooling of machine. 
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Double impression  
Reason: uncontrolled movement of punches with engravings on them. 
Remedy: Using ant turning device.       
 
 ANALYTICAL DATA ALFUZOSIN DRUG % RELEASE 
 DISSOLUTION
  
Invitro dissolution study 
 Invitro release studies were carried out by using United States Pharmacopoeia (USP) 23 
Dissolution Testing Apparatus II (Paddle method). The dissolution test was performed using 900 
ml of 0.1N HCl (pH 1.2) at 37±0.5oC. 50 rpm was maintained, 5 ml of sample was withdrawn at 
predetermined time intervals for 24 hours and the same volume of the fresh medium was 
replaced. The absorbance of the withdrawn sample was measured spectrophotometrically at a 
wavelength of about 294 nm and cumulative percentage drug release was calculated using an 
equation obtained from a standard curve.
15
 
Acid Resistance Stage 
Dissolution Medium: 900ml of simulated gastric fluid 
 Number of baskets   :  6 baskets 
Medium          : 0. 1N Hcl 
Type                : USP –II 
RPM                : 50 
Volume           : 900ml 
Run time          : 10hr 
            Temp             : 37± 0.5º C. 
 
Apparatus Classification in the USP 
Apparatus 1 (rotating basket) 
Apparatus 2 (paddle assembly) 
Apparatus 3 (reciprocating cylinder) 
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Apparatus 4 (flow-through cell) 
Apparatus 5 (paddle over disk) 
Apparatus 6 (cylinder) 
Apparatus 7 (reciprocating holder). 
In the present experiment apparatus 2 is used. 
 
Apparatus Classiﬁcation in the European Pharmacopoeia 
(2002) for Different Dosage Forms 
For Solid dosage forms 
 
Paddle apparatus 
Basket apparatus 
Flow-through apparatus 
 
For Transdermal patches 
 
Cell method 
 
For Special dosage forms Rotating cylinder method 
Chewing apparatus (medicated Chewing 
gums), Flow-through apparatus,  
Figure   Apparatus classification as per European pharmacopoeia 
FOURIER TRANSFORM INFRARED SPECTROSCOPY STUDIES 
Principle: Electromagnetic radiation ranging between 500cm
-1
 and 4000cm
-1
 is passed through a 
sample and is absorbed by the bondes of the molecules in the sample causing them to stretch or 
bend.The wave length of the radiation absorbed is characteristic of the bond absorbing it.
16
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Region Wavelength(µm) Wave number(cm
-1
) 
Near IR 0.78-2.5 12500-4000 
Mid IR 2.5-25.0 4000-400 
Far IR 25-200 400-10 
Table FTIR absorption peaks 
Equipment Details 
Manufacture: Shimadzu 
Software: spectrum 100. 
 The mid IR region of analytical importance. FT IR spectroscopy is used to determine the 
functional groups in the drug molecule. We can elucidate the structure of drugs. Mainly it is used 
for structural elucidation .Based on  the drug given in figure 21 and the optimized formulation 
given in figure 25 ,comparing the spectrum in both we conclude that the spectrums are correlated 
with each other. 
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TABLE FOURIER TRANSFORM INFRARED SPECTROSCOPY 
S.No Peaks Functional group 
1 3668.62 &  3346.30 OH (Alcohol) 
2 3051.96 Aromatic C-H Stretching 
3 3015.42 Alkene C-H Stretching 
4 2950.80 & 2893.72 Alkane C-H Stretching 
5 1730.91 & 1709.46 Ketone 
6 1621.74 NH (Amine) 
7 1396.31, 1372.09, 1351.93 & 1325.98 C-O (Phenol) 
8 1081.22, 1159.04, 1182.78 C-N Vibrations 
9 600-900 C-H Bending (Aromatic) 
 
Procedure: In the present  study,potassium bromide pellet method was employed .The sample 
are thoroughly mixed with dry powdered potassium  bromide .The mixture was compressed to 
form a disc  using dies .The disc was placed in the spectrophotometer  and the spectrum was 
recorded.  
Determination of floating parameter 
a) Invitro buoyancy test 
The invitro buoyancy was determined by observing floating lag time, as per the method 
described by Rosa. The tablets were placed in a 100 ml beaker containing 0.1N HCl. The time 
required for the tablet to rise to the surface and float was considered as the floating lag time.
18 
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RESULT AND DISCUSSION 
 
STANDARD GRAPH CALIBRATION CURVE OF ALFUZOSIN 
STANDARD GRAPH  RESULTS OF 0.1N HCL 
 
Concentration (mcg) Absorbance at 244nm 
10 0.121 
20 0.189 
30 0.262 
40 0.334 
50 0.406 
60 0.486 
                                                  
 
                                                                          
20mg in 50 ml further 2.5 in 100ml 
  
5 in 100ml 
  
7.5 in 100ml 
  
10 in 100ml 
  
12.5 in 100ml 
  
15 in 100 ml 
y = 0.0073x + 0.0449 
R² = 0.9995 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0 20 40 60 80 
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ASSAY OF ALFUZOSIN 
  
 
AF1 AF2 AF3 AF4 AF5 AF6 AF7 AF8 AF9 
Std.wt 20 
         
std.abs 0.334 
         
spl.wt 
 
121 122 120 119 120.6 123 122 121 124 
spl.abs 
 
0.302 0.308 0.306 0.298 0.304 0.307 0.31 0.308 0.312 
std.dil.f 0.002 
         
spl.dil.f 0.002 
         
std.purity 99.8 
         
  %Assay 14.92 15.09 15.24 14.97 15.06 14.92 15.19 15.21 15.04 
 
std-20mg in 50 ml further 10 
ml in 100 ml 
spl-120mg in 50 ml further 10 
ml in 100ml 
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DISSOLUTION STUDIES 
                  Table Dissolution table of formulations in 0.1N HCL 
  1HR 2HR 4HR 6HR 8HR 10HR 
AF1 16.12 21.5 44.79 60.92 77.05 96.76 
AF2 18.51 27.47 53.16 67.49 81.23 86.6 
AF3 32.85 44.2 59.13 75.26 84.81 93.17 
AF4 60.92 72.87 88.4 94.37 94.97 94.97 
AF5 36.43 46.58 64.5 76.45 86.01 95.56 
AF6 17.91 24.48 56.74 78.84 87.2 98.55 
AF7 60.92 72.27 81.23 88.99 90.19 91.38 
AF8 86.01 93.17 94.97 94.97 94.97 94.97 
AF9 14.93 19.13 40.01 53.16 71.67 83.02 
 
GRAPHS OF DISSOLUTION STUDIES 
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PRE AND POST FORMULATION STUDIES 
 
 
Table    Pre-compression parameters of Alfuzosin 
 
 
Formulation 
Bulk 
Density(gm\ml) 
Tapped 
Density(gm\ml) 
Compressabilit
y Index 
Hausner’s 
Ratio 
Angle Of 
Repose 
F1 0.4 0.476 19 1.19 36.7 
F2 0.408 0.50 22.5 1.22 42 
F3 0.4 0.512 28 1.28 46 
F4 0.416 0.512 23.2 1.23 42.5 
F5 0.4 0.487 21.7 1.21 41.7 
F6 0.416 0.512 23.27 1.23 43.2 
F7 0.411 0.552 25.5 1.34 43 
F8 0.41  0.495 24.3 1.20 36 
F9 0.413  0.503 22.5 1.21 41 
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Table     Post compression parameters of Alfuzosin 
 
 
Formulation 
Avg.Wt 
(mg) 
Thickness 
(mm) 
Diameter(mm) 
Hardness 
(Kg\cm
2
) 
Friability 
Buoyancy 
lag Time 
(sec) 
Total 
floating 
time 
(hrs) 
F1 121 2.8 7 5.5 0.14 05 <10 
F2 120.1 2.6 7 5.4 0.09 04 <12 
F3 121.4 2.5 7 5.6 0.12 05 <10 
F4 120.6 2.8 7 6 0.07 04 <12 
F5 120 2.7 7 5.1 0.2 10 <10 
F6 120.1 2.6 7 5.4 0.07 08 <10 
F7 120.6 2.6 7 5.5 0.12 08 <10 
F8 120.1 2.6 7 5.5 0.14 05 <12 
F9 120 2.65 7 5.4 0.09 04 <10 
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FOURIER TRANSFORM INFRARED SPECTROSCOPY OF ALFUZOSIN 
1. Alfuzosin 
2. Alfuzosin with HPMC K4M 
 
3. Alfuzosin with Carbopol 940p 
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4. Alfuzosin with NaHCO3 
5. 
5. Alfuzosin with Magnesium Stearate 
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STABILITY STUDIES 
Table     Stability Data of Formulation 6 at 40  2
0
C / 75  5% RH. 
Sl. 
No. 
Time in days Physical changes 
Percentage 
of drug 
content
*
±SD 
 
 
Moisture 
content 
Percentage 
of drug 
release 
*
±SD 
(99.5% of 
release label 
claim in 10 
min). 
 
1. 1
st
 day (initial) 
Round, white color 
uncoated tablets 
with Concave shape 
 
 
99.51±0.48 
 
 
0.82 
 
 
99.5% 
2. 30
th
 day (1 month) No changes 99.35±0.11 0.78 99.2% 
3. 60
th
 day (2 month) No changes 98.12±0.13 0.80 99.3% 
4. 90
th
 day (3 month) No changes 97.81±0.28 0.78 99.2% 
* SD- Standard deviation 
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  GRAPH SHOWING % DRUG CONTENT. 
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DISCUSSION 
 In the present study, an attempt has been made to formulate and evaluate floating tablets 
of Alfuzosin by wet granulation method; employing swellable polymers like 
Hydroxypropylmethycellulose (HPMC K4M), Carbopol940p, are taken along with other 
excepients nine formulations are prepared. The formulation is subjected to both pre and post 
formulation studies. 
Hardness and friability: The hardness of the tablet formulations was found to be in the range of 
5.1 to 6 kg/cm
2
 (Tables-). The friability values were found to be in the range of 0.07 to 0.14 %.( 
Tables-). 
Uniformity of weight: All the prepared tablets of moxifloxacin hydrochloride were evaluated 
for weight variation. The weight of all the tablets was found to be uniform with low values of 
standard deviation and within the prescribed IP limits of ±5%.  
Uniformity of drug content: The low values of standard deviation indicates uniform drug 
content within the tablets The percent drug content of all the tablets was found to be in the range 
of 14.92mg to 15.19mg per tablet (which was within the acceptable limits of ±5%. Tables-) 
In vitro dissolution study: In vitro dissolution studies were performed in 0.1N HCL on the 
above promising formulation, namely, formulation 6 .The results are shown in Table- and Table-
. 
Buoyancy lag Time was observed 04 to 10secnods. 
Total floating time (hrs) was observed 10 to 12hours. 
 
FTIR STUDIES. 
 There is interaction Find in above IR graphs.IR spectra of drug and formulation along 
with other excipients are shown in figures. 
Short-term stability studies Short-term stability studies on the above promising formulations 
(at 40
0
C/ 75% RH for 3 months) have shown no significant changes in physical appearance, drug 
content data of the promising formulation are shown in Tables and figure.
Summary 
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SUMMARY 
Pre compression parameters of granules 
 It is observed that the results of angle of repose were found to be ranged from 24.69 to 
27.7. 
 It is observed that the Loose Bulk Density and Tapped Bulk Density were found to be 
ranged from 0.4 to 0.416 and 0.476 to 0.552 respectively, which are found to be within the 
prescribed limits.  
 The Hausner’s ratio of the granules was found to be ranged from 1.19 to 1.34. 
 It is observed that the Compressibility index (%) is found to be ranged from 19 to 28.  
 
Post compression parameters of floating tablets: 
 It is observed that the tablets prepared in all the formulations were found to be off white, 
smooth, flat faced circular with no visible cracks. 
 The thickness and diameter of tablets were measured by vernier calipers and are found to 
be ranged from 2.6 mm to 2.8 and 7mm respectively. 
 The hardness of the tablets was measured by using Monsanto hardness tester and is found 
to range from 5.1 to 6 kg/cm
2
. The hardness of the tablets in all the formulations is found 
to be within prescribed limits. 
 The friability was measured by using Friabilator and was found to be ranged from 0.09 to 
0.14, which is an indication of satisfactory mechanical resistance of tablet. 
 The drug content estimation showed values in the range of 14.92mg/tab to 15.19mg/tab 
which reflects good uniformity in drug content among different formulations variation 
was found within the IP limit of ±5%. 
 The weight variation test was ranged from 120 to 121.4. The percentage weight variation 
was found within the IP limit of ±5% of the weight. 
 All the formulations showed the values within the prescribed limits for tests like 
hardness, friability, weight variation, drug content which indicate that the prepared tablets 
are of standard quality. 
 
Summary 
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Invitro dissolution studies: 
 Invitro dissolution studies of all formulations of floating tablets were carried out in 0.1N 
HCl. The study was performed for 10hrs and the cumulative drug release was calculated 
at every 60 min interval.  
 The invitro drug release for formulations with polymer HPMC K15M (F1 to F9) was 
ranged from 83.02 to98.55 % for 10hrs 
 The maximum invitro drug release for formulations with polymer HPMC K15M (F6) was 
ranged from 98.55% for 10hrs. 
 The higher rate and extent drug release was observed from the formulations based on 
HPMC K4M polymer. Varying the amount of HPMC K4M affect the drug release. 
 The drug release from K15M and Carbapol was lesser owing to its high viscosity and less 
permeability of water. 
Conclusion 
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CONCLUSION 
 
 In the present work, floating tablets of Alfuzosin were prepared by Direct Compression 
method. All the tablets were subjected to weight variation, drug content uniformity, and 
hardness, and friability, water absorption ratio, wetting time, dissolution, drug excipients 
interaction and short-term stability studies.  
Based on the above study following conclusions can be drawn:  
 Tablets prepared by wet granulation method were found to be good without any chipping, 
capping and sticking.   
 The hardness of the prepared tablets was found to be in the range of 5.4 to 6 kg/ cm2.  
 The friability values were found to be in the range of 0.07 to 0.14 %.  
 Formulation six showed good results than rest of the nine formulations in pre and post 
compression studies. 
 The low values of standard deviation for average weight and drug content of the prepared 
tablets indicate weight and drug content uniformity within the batches prepared.  
 Formulations 6 displayed drug release considered in 0.1N HCL and Formulation 6 shows 
better drug release in dissolution profile. 
 Short-term stability studies of promising formulations indicated that there are no 
significant changes in drug content.  
 IR-spectroscopic studies indicated that there are no drug–excipients interactions.  
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